

**National Institute for Health and
Care Excellence**

Acute Respiratory Infection in over 16s: Initial assessment and management

**[D] Evidence summary for acute
respiratory infection**

NICE guideline [XXX]

Evidence reviews underpinning recommendations 1.1.1
to 1.1.12 and research recommendations in the NICE
guideline

September 2023

Draft for consultation



Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2023. All rights reserved. Subject to [Notice of rights](#).

ISBN: xxx

Contents

1	1 Acute respiratory infection.....	5
2	1.1 Review questions	5
	1.1.1 Introduction	5
	1.1.2 Summary of the protocols	5
	1.1.3 Methods and process.....	8
	1.1.4 Effectiveness and diagnostic evidence	9
	1.1.5 Summary of studies included in the evidence	10
	1.1.6 Summary of the evidence	29
	1.1.7 Economic evidence	52
	1.1.8 Summary of included economic evidence.....	52
	1.1.9 Economic model.....	59
	1.1.10 Unit costs	59
	1.1.11 The committee’s discussion and interpretation of the evidence	63
	1.1.12 Recommendations supported by this evidence review	73
	1.1.13 References – included studies	73
3	Appendices	75
4	Appendix A – Review protocols	75
5	Appendix B – Literature search strategies	75
6	Appendix C – Effectiveness and diagnostic evidence study selection	75
7	Appendix D – Effectiveness and diagnostic evidence	75
8	Appendix E – Forest plots.....	75
9	Appendix F – GRADE tables	75
10	Appendix G – Economic evidence study selection	75
11	Appendix H – Economic evidence tables	75
12	Appendix I – Health economic model	75
13	Appendix J – Excluded studies.....	75
14	Appendix K– Research recommendations – full details.....	76
15	Appendix L – Methods.....	81

1 Acute respiratory infection

2 1.1 Review questions

- 3 1. In people aged 16 years or over with suspected acute respiratory infection (ARI):
 - 4 a. What are the symptoms, signs, and early warning scores (EWS) that have been
5 evaluated?
 - 6 b. What are the strategies for the triage of patients (for example, applying clinical
7 prediction rules using symptoms, signs, EWS thresholds) to avoid serious illness?
- 8 2. What is the clinical effectiveness and cost-effectiveness of different near-patient, rapid
9 microbiological or biomarker tests alone or in combination to guide initial assessment and
10 management in people aged 16 and over with suspected ARI?
- 11 3. In people aged over 16, what is the diagnostic accuracy of near-patient, rapid tests to
12 distinguish between bacterial and viral infection in suspected acute respiratory infection?

13 1.1.1 Introduction

14 Before the COVID-19 pandemic, people with suspected acute respiratory infections either
15 presented to NHS111 or primary care for assessment and management, with more severe
16 cases referred for hospital assessment, or they presented directly to A&E or to the
17 ambulance service if their symptoms were more serious. Since the pandemic, the levels of
18 acute respiratory infection (particularly pneumonia caused by COVID-19 infection) have
19 increased.

20 In response to this the NHS has set up a number of [acute respiratory infection \(ARI\) hubs](#)
21 and [acute respiratory infection virtual wards](#) to relieve pressure on other parts of the local
22 healthcare system.

23 NICE has been asked to produce a number of related products to support and inform the
24 expansion of virtual ward provision and other intermediate care areas. This guideline will aid
25 healthcare professionals in deciding where to refer people aged 16 and over with suspected
26 acute respiratory infections including referrals to Virtual Wards and ARI Hubs.

27 1.1.2 Summary of the protocols

28 These 3 tables are reproduced from the relevant evidence reviews. See below for details.

29 **Table 1: RQ1: Symptoms, signs, and early warning scores**

Population	People aged 16 years or over with suspected ARI (including bronchitis, common cold, glandular fever, influenza, laryngitis, sore throat (pharyngitis and tonsillitis), pneumonia and severe acute respiratory syndrome (SARS)). Exclusion criteria: People aged 16 or over with a confirmed COVID-19 diagnosis, who are hospital in-patients, who have a respiratory infection during end-of-life care,
------------	--

	and those with aspiration pneumonia, bronchiectasis, cystic fibrosis, or known immunosuppression.
Phenomenon of interest	Symptoms, signs and externally validated EWS for the assessment of suspected ARI, including: cough, coughing up blood, purulent sputum, malaise, coryza, temperature/signs of fever, sore throat, hoarse voice, breathlessness and/or increased respiratory rate, wheeze/chest tightness, cyanosis, loss of appetite, lethargy, agitation, confusion, delirium, drowsiness, headache, rigors, chest pain, monitoring parameters based on digital technologies where available (e.g. pulse oximetry, peak flow), sudden deterioration in any of the above, EWS (including NEWS/NEWS2, CRB-65/CURB-65, CENTOR criteria), and any combination of the above.
Outcomes	<p>Assessed within 4 weeks of consultation:</p> <ul style="list-style-type: none"> • Hospital admission • Escalation of care to any setting including: <ul style="list-style-type: none"> ○ Face to face consultation ○ Re-consultation/appointment ○ Virtual ward ○ Referral to ARI hub ○ A&E visit • Unplanned hospital admission • Hospital length of stay • Follow-up consultation/ongoing monitoring • Antibiotic/antiviral use • Time to clinical cure/resolution of symptoms • Mortality <p>Secondary outcomes:</p> <ul style="list-style-type: none"> • Patient acceptability • Patient preference • HRQoL (using a validated scale)
Study type	Systematic reviews.

1 For the full protocol see [Evidence review A](#) (Appendix A).

2

3 **Table 2: RQ2: Different near-patient, rapid microbiological or biomarker tests**

Population	<p>Inclusion criteria</p> <p>People aged 16 years or over with suspected acute respiratory infection.</p> <p>Exclusion criteria</p> <p>People aged 16 years or over:</p> <ul style="list-style-type: none"> • With a confirmed COVID-19 diagnosis (patients with known COVID will be triaged in a different way, suspected COVID would be treated as suspected ARI). • All inpatients in hospital.
------------	--

	<ul style="list-style-type: none"> • Who have a respiratory infection during end-of-life care. • With aspiration pneumonia, bronchiectasis, cystic fibrosis or known immunosuppression. • Who are presenting with acute respiratory infections that rarely require or lead to escalation of care to hospital admission such as otitis media and sinusitis.
Intervention	<p>Near patient, rapid tests (turnaround time \leq 45mins, also known as point of care tests) which are currently licensed and available for use in the UK as follows:</p> <ul style="list-style-type: none"> • Rapid antigen test • Rapid PCR tests • Urinary antigen tests • C-reactive protein • Procalcitonin • Serum sodium • Urea nitrogen • Partial pressure O₂ • Blood gases • Full blood count • White blood cell count • Myxovirus resistance protein A • TNF-related apoptosis-induced ligand (TRAIL) • Interferon-γ-induced protein-10 (IP-10)
Comparator	Current practice
Outcomes	<ul style="list-style-type: none"> • Hospital admission (immediately after triage or at 28 days) • Escalation of care (some time after initial consultation): <ul style="list-style-type: none"> ○ Re-consultation/appointment ○ Virtual Ward ○ Emergency department visit ○ Unplanned hospital admission • Hospital length of stay • Follow-up consultation/ongoing monitoring • Antibiotic/antiviral use • Time to clinical cure/resolution of symptoms • Mortality • HRQoL (using a validated scale)
Study type	<p>Systematic reviews. Randomised controlled trials</p>

1 For the full protocol see [Evidence review B](#) (Appendix 1).

2

1 **Table 3: RQ3: Accuracy of near-patient, rapid tests to distinguish between**
 2 **bacterial and viral infection in suspected ARI**

Population	People aged 16 years or over with suspected acute respiratory infection, including (but not limited to) the following symptoms: <ul style="list-style-type: none"> • Cough or shortness of breath • Sore throat • Rhinitis
Index tests	<ul style="list-style-type: none"> • Symptoms and signs of acute respiratory infection; either individual symptoms/signs, or in combination (as part of a clinical decision tool) • “Host-response” (or “biomarker”) point of care tests (POCTs), including: <ul style="list-style-type: none"> ○ CRP ○ Procalcitonin ○ CRP and MxA (FebriDx) ○ TRAIL, IP-10 and CRP (ImmunoXpert/MeMed BV) ○ White cell differential count • Multiplex or single POCTs (with a turnaround time of <45 minutes) for (or including) the following specific organisms: <ul style="list-style-type: none"> ○ Influenza (A and B) ○ Respiratory syncytial virus (RSV)
Comparator/Reference standard	Any reference standard
Outcomes	Diagnostic accuracy measures <ul style="list-style-type: none"> • Sensitivity • Specificity • Area under the curve (AUC)
Study type	Diagnostic test accuracy studies

3 For the full protocol see [Evidence review C](#) (Appendix A).

4 **1.1.3 Methods and process**

5 This evidence summary summarises the evidence from 3 rapid systematic reviews
 6 undertaken for NICE by 3 NIHR-funded Evidence Synthesis Groups. The summaries of
 7 evidence presented in this document are taken from those reviews, which contain full details.

8 The 3 evidence reviews were developed using the methods and process described in
 9 [Developing NICE guidelines: the manual](#). Methods specific to this individual review questions
 10 are described in the individual reviews.

11

12

1 **Table 4: ESGs who undertook evidence syntheses**

Review question	Review	Author details	Review title
1	[A]	York Evidence Synthesis (YES) Group	Evidence review for acute respiratory infection in adults over 16 years: initial assessment and management
2	[B]	West Midlands Evidence Synthesis Group	Rapid tests to inform triage and antibiotic prescribing decisions for adults presenting with suspected acute respiratory infection: A rapid evidence synthesis of clinical effectiveness and cost-utility studies
3	[C]	Bristol Evidence Synthesis Group	Evidence reviews for diagnostic accuracy of point of care tests for viral vs bacterial infection

2 Declarations of interest were recorded according to [NICE's conflicts of interest policy](#).

3 **1.1.4 Effectiveness and diagnostic evidence**

4 **1.1.4.1 Included studies**

5 See [individual reviews](#) for details of the searches and the number of studies identified at
6 each stage of sifting.

7 A study selection summary is presented as a PRISMA diagram in an appendix in each
8 review.

9 Full references of the included studies can be found in each review.

10 **1.1.4.2 Excluded studies**

11 Details of studies excluded at full text, along with reasons for exclusion are given in an
12 appendix of each review.

1 **1.1.5 Summary of studies included in the evidence**

2 The summaries of studies tables are presented below for each of the evidence reviews. Fuller details are included in each [evidence review](#).

3 **Table 5: RQ1: Symptoms, signs, and early warning scores – included studies**

Study details	Population	Setting	Prognostic factors/ Prognostic model(s)	Outcomes	Risk of bias
Individual signs/symptoms and Centor score for adults presenting with sore throat symptoms					
Aalbers (2011) ² Systematic review including 21 studies	Adults (≥15 years of age) presenting with sore throat symptoms	Primary care and the emergency department (USA, Canada, Europe, New Zealand, Thailand, Israel)	Individual symptoms and signs (absence of cough, fever, anterior cervical adenopathy, tender anterior cervical adenopathy, any exudates) and Centor score	Usefulness of individual symptoms and signs in assessing the risk of streptococcal pharyngitis and diagnostic accuracy of the Centor score as a decision rule for antibiotic treatment	Low
Early warning scores (EWS) for patients with community acquired pneumonia (CAP)					
Akram (2011) ³ Systematic review including 13 studies	Outpatients with community acquired pneumonia (CAP)	Outpatients; either exclusively managed in the community or discharged from an emergency department <24 hours after admission (USA, Canada, Netherlands, Germany, Spain, France, UK)	CRB65, CURB65 and Pneumonia Severity Index (PSI)	Outpatient mortality and diagnostic accuracy	Low
Chalmers (2011) ⁴ Systematic review including 6 studies	Outpatients with CAP	Emergency department and walk-in medical centre (USA, Canada, Spain, France)	PSI and other criteria for assessing severity/requirement for in-patient care	Proportion of patients treated as outpatients, mortality, hospital re-admissions, health related quality of life, return to usual activities and patient satisfaction with care.	Low
Ebell (2019) ⁵ Systematic review including 29 studies; 15 were in emergency department or	Patients with CAP	The review included hospitalised patients, ambulatory patients and both; the 15 studies that included patients in emergency department or	CRB-65	Prediction of mortality	High

Study details	Population	Setting	Prognostic factors/ Prognostic model(s)	Outcomes	Risk of bias
primary care settings (update of McNally 2010)		primary care settings are relevant to this review (most studies from Europe)			
McNally (2010) ⁶ Systematic review including 14 studies; 4 included community-based patients	Adults (≥16 years of age) with a primary diagnosis of CAP	The review included hospitalised patients, primary care patients and patients treated as outpatients; the 4 studies that included primary care patients and patients treated as outpatients are relevant to this review (study location not reported)	CRB-65	30-day mortality	Low
Metlay (2019) ⁷ Systematic review including 7 studies relating to the question of interest	Adults diagnosed with CAP	Inpatient versus outpatient treatment location (study location not reported)	PSI and CURB-65	Initial site of treatment	High
Nannan Panday (2017) ⁸ Systematic review including 42 studies; 4 included patients with CAP or respiratory distress	Adults (≥16 years of age) at the emergency department or acute medical unit	Emergency department and acute medical unit (Denmark, Netherlands, Norway, Germany, Hong Kong, Ireland, Israel, Italy, Singapore, South Africa, South Korea, Sri Lanka, Sweden, Switzerland,	25 different types of early warning score (EWS). For the 4 studies relevant to our question, the scores assessed were Chronic Respiratory Early Warning Score (CREWS), CRB-65, CURB-65, National Early Warning Score (NEWS), PSI, Systemic Inflammatory Response Syndrome (SIRS), Standardised	Prediction of mortality and/or intensive care unit (ICU) admission	Low

Study details	Population	Setting	Prognostic factors/ Prognostic model(s)	Outcomes	Risk of bias
		Turkey, UK, USA and Vietnam)	Early Warning Score (SEWS) and Salford National Early Warning Score (S-NEWS)		
Smith (2021) ⁹ Systematic review including 38 studies relating to the question of interest	Adult emergency department patients diagnosed with CAP	Emergency department (USA, Spain, Switzerland, Australia, Canada, China, France, Japan, Korea, Turkey, UK and Europe, where reported)	PSI and CURB-65 for predicting mortality. 5 clinical decision aids for predicting the need for ICU admission: American Thoracic Society (ATS) 2001, Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) 2007, Severe CAP (SCAP/CURXO-80), SMART-COP, Risk of Early Admission to the ICU (REA-ICU)	Prediction of mortality (PSI and CURB-65) and prediction of need for ICU admission (ATS 2001, IDSA/ATS 2007, SCAP/CURXO-80, SMART-COP and REA-ICU)	Unclear
Early warning scores (EWS) for patients with nursing home acquired pneumonia (NHAP)					
Dosa (2005) ¹⁰ Systematic review including 3 studies relating to the question of interest	Nursing home residents with nursing home acquired pneumonia (NHAP)	Nursing homes (USA)	PSI, a 5-point scale developed by Naughton and Mylotte and an 8-variable model developed by Mehr et al.	Prediction of mortality	High

1 Abbreviations: ATS = American Thoracic Society; CAP = community acquired pneumonia; EWS = early warning scores; ICU = intensive care unit; IDSA/ATS =
2 Infectious Diseases Society of America/American Thoracic Society; MEDS = Mortality in Emergency Department Sepsis score; MEWS = Modified Early Warning
3 Score; NEWS = National Early Warning Score; NHAP = nursing home acquired pneumonia; PSI = Pneumonia Severity Index; REA-ICU = Risk of Early Admission to
4 the ICU; REMS = Rapid Emergency Medicine Score; SCAP = Severe CAP.

5
6

1 **Table 6: RQ2: Different near-patient, rapid microbiological or biomarker tests - Characteristics of included studies for C-**
 2 **reactive protein point of care tests**

3

Study Details	Participants	Interventions	Outcomes	Comments ^a
Afinion CRP point-of-care testing				
Andreeva 2014 ²⁹ Russia Open-label cluster RCT January to April 2010 Follow-up: 14 days	179 patients: CRP 101, usual care 78 Acute cough/lower RTI for < 28 days	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> • Antibiotics prescribed at index consultation • Antibiotics prescribed within 14 days • Hospital admission (not stated, assume within 14 days) • Number of re-consultations within 14 days • Number of participants fully or almost recovered within 14 days 	Funding: Not reported. Test kits provided by manufacturer and CRP readers acquired at reduced prices. Overall risk of bias: High
Butler 2019 ²⁴ Francis 2020 ³⁴ UK (England & Wales) Open-label RCT January 2015 to September 2017	649 patients: CRP 325, usual care 324 Acute exacerbation of COPD between 24 hours and 21 days duration	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> • Antibiotics prescribed at index consultation • Antibiotics prescribed within 28 days • Antibiotics prescribed within 4 weeks post-randomisation (patient-reported) • Mortality within 28 days • Hospital admissions within 6 months • Primary and/or secondary care consultations during 6 months follow-up • HRQoL (EQ-5D-5L index value) at 1, 2 and 4 weeks and at 6 months 	Funding: Non-commercial Overall risk of bias: High

Study Details	Participants	Interventions	Outcomes	Comments ^a
Follow-up: 4 weeks and 6 months			<ul style="list-style-type: none"> HRQoL (EQ-5D-5L health status) at 1, 2 and 4 weeks and at 6 months HRQoL (CRQ-SAS)	
Nycocard II CRP point-of-care testing (<i>Not currently available in the UK</i>)				
Althaus 2019 ³⁰ Thailand and Myanmar Open-label RCT June 2016 to June 2017 Follow-up: Day 5 + 14	937 patients (adults subgroup) CRP 614, usual care 323 Documented fever or chief complaint of fever (< 14 days)	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> Antibiotics prescribed at index consultation 	Funding: Non-commercial Overall risk of bias: High
Cals 2009 ²⁶ Cals 2013 ³⁵ The Netherlands Open-label cluster-RCT Winter periods 2005-06 and 2006-07 Follow-up: 28 days	431 patients CRP 227, usual care 204 Suspected lower respiratory tract infection	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> Antibiotics prescribed at index consultation Antibiotics prescribed within 28 days Mortality during 28 days Hospital admissions during 28 days Number of re-consultations within 28 days Number of participants substantially improved within 28 days 	Funding: Non-commercial Overall risk of bias: High

Study Details	Participants	Interventions	Outcomes	Comments ^a
Diederichsen 2000 ³¹ Denmark Open-label RCT January to April 1997 Follow-up: 1 week	673 patients CRP 342, usual care 331 All patients with index case of respiratory infection	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> Antibiotics prescribed at index consultation 	Source of funding: Not reported Overall risk of bias: High
Do 2016 ³³ Northern Vietnam Open-label RCT March 2014 to July 2015 Follow-up: 14 days	1008 patients CRP 507, usual care 501 Non-severe acute respiratory tract infection	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> Antibiotics prescribed at index consultation Antibiotics prescribed within 14 days (per protocol analysis) Subsequent antibiotic use in those without an immediate antibiotic prescription Antibiotic management change in those without an immediate antibiotic prescription Time to resolution of symptoms Mortality within 14 days 	Funding: Non-commercial Overall risk of bias: High
Melbye 1995 ³² Norway Open-label RCT	239 patients CRP 108, usual care 131 Suspected lower RTI	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> Antibiotics prescribed at index consultation Antibiotics prescribed within 28 days Number of participants substantially improved within 7 days Number of participants substantially improved within 28 days 	Funding: Nycomed Pharma Study terminated early due to parity at interim analysis and lack of interest in

Study Details	Participants	Interventions	Outcomes	Comments ^a
Study dates not reported Follow-up: 3 weeks				participating practices. Overall risk of bias: High
QuikRead CRP				
Boere 2021 ²⁷ Boere 2022 ³⁶ The Netherlands Open-label cluster RCT September 2018 to March 2020 Follow-up: 3 weeks	241 patients CRP 162, usual care 79 Nursing home residents with suspected LRTI	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> • Antibiotics prescribed at index consultation (including subgroup analysis for COPD) • Antibiotic treatment changes (start, cessation, switch, or prolongation) • Mortality within 3 weeks • Hospital admission within 3 weeks • Hospitalisation at initial consultation • Hospitalisation at 1 and 3 weeks • Number of participants substantially improved within 3 weeks • Number of participants fully recovered at 3 weeks 	Funding: Non-commercial Overall risk of bias: High
Cals 2010 ²⁸ The Netherlands Open-label RCT November 2007 to April 2008	258 patients CRP 129, usual care 129 Suspected acute LRTI or rhinosinusitis	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> • Antibiotics use after index consultation (immediate prescription and/or delayed prescription and filled) • Antibiotics prescribed within 28 days • Mortality within 28 days • Hospital admissions within 28 days • Number of re-consultations within 28 days 	Funding: Orion Diagnostica Espoo, Finland Overall risk of bias: High

Study Details	Participants	Interventions	Outcomes	Comments ^a
Follow-up: 28 days			<ul style="list-style-type: none"> Number of participants substantially improved within 7 days Patient reported time to full recovery 	
Little 2013 ²⁵ Little 2019 ³⁷ Belgium, UK, Poland, Spain, The Netherlands Open-label cluster-RCT February 2011 to May 2012 Follow-up: 12 months	1932 patients CRP 1062, usual care 870 Upper or lower respiratory tract infection	Interventions: Single POC CRP Comparator: usual care	<ul style="list-style-type: none"> Hospital admissions within 4 weeks Number of re-consultations within 28 days Resolution of moderately bad symptoms, Mortality 	Funding: Non-commercial Overall risk of bias: High
^a Overall risk of bias: see Error! Reference source not found. in evidence review B for details. Abbreviations: AECOPD – acute exacerbation of chronic obstructive pulmonary disease; ARI – acute respiratory infection; COPD – chronic obstructive pulmonary disease; CRP – C-reactive protein; CRQ-SAS - Chronic Respiratory Disease Questionnaire; EQ-5D-5L - European Quality of Life–5 Dimensions 5-Level questionnaire; GP – general practice; POC – point-of-care; RCT – randomised controlled trial; RTI – respiratory tract infection.				

1
2

1 **Table 7: RQ2: Different near-patient, rapid microbiological or biomarker tests - Characteristics of included studies for**
 2 **procalcitonin tests**

Study Details	Participants	Interventions	Outcomes and Results	Comments ^a
BRAHMS PCT Procalcitonin				
Lhopitallier 2021 ³⁸ Switzerland Open-label cluster-RCT September 2018 to March 2020 Follow-up: 28 days	469 patients Procalcitonin 195, usual care 122 Lower RTI/acute cough	Interventions: POC procalcitonin Comparator: usual care	<ul style="list-style-type: none"> • Antibiotics prescribed at index consultation • Antibiotics prescribed within 7 days • Antibiotics prescribed within 28 days • Number of re-consultations within 28 days • Hospital admissions within 7 days • Mortality within 28 days • Duration of symptoms by day 28 	Funding: Non-commercial. POC test kits were provided by the manufacturer Overall risk of bias: High
^a Overall risk of bias: see Error! Reference source not found. for details. Abbreviations: POC – point-of-care; RCT – randomised controlled trial; RTI – respiratory tract infection.				

3
4

5 **Table 8: RQ2: Different near-patient, rapid microbiological or biomarker tests - Characteristics of included studies for Group**
 6 **A Streptococcus tests**

Study Details	Participants	Interventions	Outcomes and Results	Comments ^a
RADT OSOM® Strep A				
Llor 2011 ³⁹	557 patients RADT 285, usual care 272	Interventions: RADT OSOM® Strep A test	<ul style="list-style-type: none"> • Antibiotics prescribed at index consultation 	Funding: Non-commercial

Study Details	Participants	Interventions	Outcomes and Results	Comments ^a
Spain Open-label cluster-RCT January to May 2008 Follow-up: NR	Acute pharyngitis	Comparator: usual care		Includes patients aged ≥14 years, slight difference to current review criteria. Overall risk of bias: High
RADT Clearview® Exact Strep A				
Worrall 2007 ⁴⁰ Canada Open-label cluster-RCT February to April 2005 Follow-up: NR	533 patients RADT 120, usual care 141 Acute sore throat as primary symptom	Interventions: RADT Clearview® Exact Strep A dipstick Comparator: usual care	<ul style="list-style-type: none"> Antibiotics prescribed at index consultation 	Funding: Not reported Overall risk of bias: High
^a Overall risk of bias: see Error! Reference source not found. for details. Abbreviations: NR – not reported; POC – point of care; RADT – rapid antigen detection test; RCT – randomised controlled trial.				

1
2

1
2

Table 9: RQ2: Different near-patient, rapid microbiological or biomarker tests - Characteristics of included study for Influenza tests

Study Details	Participants	Interventions	Outcomes and Results	Comments ^a
BD Directigen™ Flu A + B rapid test (Not currently available in the UK)				
Berthod 2015 ⁴¹ NCT00821626 ⁴² Switzerland Open-label RCT December 2008 to November 2012 Follow-up: NR	93 patients RADT 60, usual care 33 Fever or cough or sore throat within 4 days; illness within 14 days of a trip abroad	Interventions: BD Directigen A + B Comparator: usual care	<ul style="list-style-type: none"> Antibiotics prescribed at index consultation Mortality	Funding: Not reported Trial finished early due to low sensitivity of the intervention. Overall risk of bias: High
^a Overall risk of bias: see Error! Reference source not found. for details. Abbreviations: NR – not reported; RADT – rapid antigen detection test; RCT – randomised controlled trial.				

3
4
5
6

1
2

Table 10: RQ3: Accuracy of near-patient, rapid tests to distinguish between bacterial and viral infection in suspected ARI – Systematic reviews

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias (ROBIS)
Carlton 2021	Adults and children presenting with symptoms of acute respiratory tract infection.	<ul style="list-style-type: none"> • TRAIL, IP-10 and CRP (ImmunoXpert) • CRP and MxA (FebriDx) • CRP and neopterin 	Any reference standard, including consensus of an expert panel, clinical algorithms and microbiology.	<ul style="list-style-type: none"> • Bacterial respiratory tract infection • Viral respiratory tract infection 	Low risk of bias
Gentilotti 2022	Adults and children with symptoms of acute respiratory infection, presenting to primary/emergency care settings.	<ul style="list-style-type: none"> • Individual symptoms and signs • CRP • Procalcitonin • Various POC tests for influenza 	Any reference standard, including chest X-ray, microbiological assessment, expert opinion.	<ul style="list-style-type: none"> • Bacterial pneumonia • Influenza 	Low risk of bias
Minnaard 2017	Adults with suspected lower respiratory tract infection, presenting to primary/emergency care settings.	Clinical prediction models incorporating combinations of symptoms and signs plus CRP measurement	Chest X-ray	<ul style="list-style-type: none"> • Pneumonia 	Low risk of bias
Onwuchekwa 2023	Adults and children. No information on clinical presentation.	Any tests for RSV	RT PCR	<ul style="list-style-type: none"> • RSV 	Low risk of bias
Pazmany 2021	Adults with COPD, presenting with an acute exacerbation to primary care/emergency department or in hospital.	Presence of purulent sputum	Microbiological culture	<ul style="list-style-type: none"> • Bacterial exacerbation of COPD 	Low risk of bias

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias (ROBIS)
Schierenberg 2017	Adults with an acute or worsened cough or lower respiratory tract infection, present to primary or emergency care.	Combinations of symptoms and signs (clinical prediction models)	Chest X-ray, CT or MRI	<ul style="list-style-type: none"> Pneumonia 	Low risk of bias
COPD chronic obstructive pulmonary disease; CRP C reactive protein; CT computed tomography; IP-10 interferon-γ-induced protein-10; MRI magnetic resonance imaging; MxA myxovirus resistance protein A; POC point of care; RSV respiratory syncytial virus; RT PCR real time polymerase chain reaction; TRAIL TNF-related apoptosis-induced ligand					

1

2

3

4

Table 11: RQ3: Accuracy of near-patient, rapid tests to distinguish between bacterial and viral infection in suspected ARI – Primary studies included in the diagnostic evidence for white cell differential count

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias (QUADAS 2)
Castro-Guardiola 2000	Adults (n = 284) with suspected pneumonia in an emergency department	<ul style="list-style-type: none"> White blood cell count 	Chest X-ray, plus clinical symptoms and signs	<ul style="list-style-type: none"> Pneumonia 	<i>Risk of bias:</i> Patient selection: low risk Index test: low risk Reference standard: high risk Flow and timing: low risk <i>Applicability:</i> Patient selection: low concern Index tests: high concern Reference standard: low concern

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias (QUADAS 2)
Gulich 1999	Adults (n = 179) with sore throat, presenting to primary care	<ul style="list-style-type: none"> White blood cell count 	Microbiological culture	<ul style="list-style-type: none"> Bacterial pharyngitis 	<p><i>Risk of bias:</i></p> <p>Patient selection: low risk Index test: low risk Reference standard: low risk Flow and timing: low risk</p> <p><i>Applicability:</i></p> <p>Patient selection: low concern Index tests: high concern Reference standard: low concern</p>
Holm 2007	Adults (n = 364) with symptoms of a lower respiratory tract infection, presenting to primary care	<ul style="list-style-type: none"> White blood cell count 	Chest X-ray	<ul style="list-style-type: none"> Pneumonia 	<p><i>Risk of bias:</i></p> <p>Patient selection: high risk Index test: high risk Reference standard: low risk Flow and timing: high risk</p> <p><i>Applicability:</i></p> <p>Patient selection: low concern Index tests: high concern Reference standard: low concern</p>
Liu 2013	Adults (n = 500) with a diagnosis of community acquired pneumonia in an outpatient clinic	<ul style="list-style-type: none"> White blood cell count 	Microbiological culture and PCR	<ul style="list-style-type: none"> Bacterial pneumonia 	<p><i>Risk of bias:</i></p> <p>Patient selection: unclear risk Index test: unclear risk Reference standard: low risk Flow and timing: low risk</p> <p><i>Applicability:</i></p>

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias (QUADAS 2)
					Patient selection: low concern Index tests: high concern Reference standard: low concern

1

1 **Table 12: RQ3: Accuracy of near-patient, rapid tests to distinguish between bacterial and viral infection in suspected ARI –**
 2 **Primary studies included in the diagnostic evidence for multiplex PCR tests**

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias
Boku 2013	Adults with acute respiratory infection or fever and contact with influenza in a hospital outpatient setting	<ul style="list-style-type: none"> Verigene system RV+ 	Viral culture plus laboratory PCR	<ul style="list-style-type: none"> Flu A/B 	<i>Risk of bias:</i> Patient selection: unclear risk Index test: low risk Reference standard: unclear risk Flow and timing: low risk <i>Applicability:</i> Patient selection: low concern Index tests: low concern Reference standard: low concern
Escarate 2022	Adults aged ≥65 years with symptoms of respiratory illness in a care home setting	<ul style="list-style-type: none"> Xpert Xpress Flu/RSV 	Laboratory PCR	<ul style="list-style-type: none"> Flu A Flu B RSV 	<i>Risk of bias:</i> Patient selection: unclear risk Index test: low risk Reference standard: low risk Flow and timing: high risk <i>Applicability:</i> Patient selection: high concern Index tests: low concern Reference standard: low concern
Farfour 2022	Adults with suspected viral respiratory infection in an emergency department	<ul style="list-style-type: none"> Idylla SARS CoV/Flu/RSV 	Laboratory PCR	<ul style="list-style-type: none"> Flu A RSV 	<i>Risk of bias:</i> Patient selection: low risk Index test: unclear risk Reference standard: low risk Flow and timing: high risk <i>Applicability:</i> Patient selection: low concern

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias
					Index tests: low concern Reference standard: low concern
Hansen 2018	Adults (80%) and children (20%) with at least one sign of influenza in an emergency department setting	<ul style="list-style-type: none"> Cobas Liat Influenza A/B 	Laboratory PCR	<ul style="list-style-type: none"> Flu A/B 	<i>Risk of bias:</i> Patient selection: high risk Index test: low risk Reference standard: low risk Flow and timing: low risk <i>Applicability:</i> Patient selection: low concern Index tests: low concern Reference standard: low concern
Maignan 2016	Adults with fever and at least one sign of a respiratory infection in an emergency department setting	<ul style="list-style-type: none"> Cobas Liat Influenza A/B 	Laboratory PCR	<ul style="list-style-type: none"> Flu A Flu B Flu A/B 	<i>Risk of bias:</i> Patient selection: low risk Index test: low risk Reference standard: low risk Flow and timing: low risk <i>Applicability:</i> Patient selection: low concern Index tests: low concern Reference standard: low concern
Morris 2021	Adults (and children – subgroup data for adults were used) with symptoms of acute respiratory infection, presenting to the emergency department	<ul style="list-style-type: none"> Xpert Xpress Flu/RSV 	Laboratory PCR	<ul style="list-style-type: none"> Flu A RSV 	<i>Risk of bias:</i> Patient selection: high risk Index test: low risk Reference standard: low risk Flow and timing: low risk <i>Applicability:</i> Patient selection: low concern Index tests: low concern

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias
					Reference standard: low concern
Peretz 2020	Adults with suspected influenza in an emergency department	<ul style="list-style-type: none"> Xpert Xpress Flu A/B Simplex Flu A/B and RSV 	Rapid antigen test	<ul style="list-style-type: none"> Flu A/B 	<i>Risk of bias:</i> Patient selection: unclear risk Index test: unclear risk Reference standard: high risk Flow and timing: low risk <i>Applicability:</i> Patient selection: low concern Index tests: high concern Reference standard: low concern
Tanei 2014	Adults with symptoms of acute respiratory infection and a fever $\geq 37^{\circ}\text{C}$	<ul style="list-style-type: none"> Verigene RV+ 	Rapid antigen test	<ul style="list-style-type: none"> Flu A/B 	<i>Risk of bias:</i> Patient selection: low risk Index test: unclear risk Reference standard: high risk Flow and timing: low risk <i>Applicability:</i> Patient selection: low concern Index tests: high concern Reference standard: low concern
Valentin 2019	Adults with acute, febrile respiratory tract infection with at least one risk factor for complications of influenza.	<ul style="list-style-type: none"> Xpert Xpress Flu/RSV Cobas Liat Flu A/B 	Laboratory based PCR	<ul style="list-style-type: none"> Flu A Flu B Flu A/B 	<i>Risk of bias:</i> Patient selection: low risk Index test: low risk Reference standard: low risk Flow and timing: high risk <i>Applicability:</i> Patient selection: low concern Index tests: high concern Reference standard: low concern

Study details	Population	Index test(s)	Reference standard(s)	Target condition(s)	Risk of bias
Yin 2022	Adults (77%) and children (23%) with symptoms of acute respiratory infection in an emergency department.	<ul style="list-style-type: none"> Cobas Liat Flu A/B 	Rapid antigen test plus culture plus Cobas Liat test	<ul style="list-style-type: none"> Flu A Flu B RSV 	<p><i>Risk of bias:</i></p> <p>Patient selection: unclear risk</p> <p>Index test: low risk</p> <p>Reference standard: high risk</p> <p>Flow and timing: low risk</p> <p><i>Applicability:</i></p> <p>Patient selection: low concern</p> <p>Index tests: high concern</p> <p>Reference standard: low concern</p>
Youngs 2019	Adults with suspected influenza in an emergency department	<ul style="list-style-type: none"> Cobas Liat Flu A/B 	Laboratory PCR and alternative rapid multiplex test	<ul style="list-style-type: none"> Flu A Flu B Flu A/B 	<p><i>Risk of bias:</i></p> <p>Patient selection: low risk</p> <p>Index test: low risk</p> <p>Reference standard: high risk</p> <p>Flow and timing: high risk</p> <p><i>Applicability:</i></p> <p>Patient selection: low concern</p> <p>Index tests: low concern</p> <p>Reference standard: low concern</p>
Zuurbier 2022	Adults with symptoms of acute respiratory tract infection at home or in a primary care setting	<ul style="list-style-type: none"> Xpert Xpress Flu/RSV 	Laboratory PCR	<ul style="list-style-type: none"> RSV 	<p><i>Risk of bias:</i></p> <p>Patient selection: low risk</p> <p>Index test: low risk</p> <p>Reference standard: low risk</p> <p>Flow and timing: high risk</p> <p><i>Applicability:</i></p> <p>Patient selection: high concern</p> <p>Index tests: low concern</p> <p>Reference standard: low concern</p>

1 See appendices of [individual reviews](#) for full evidence tables.

2 **1.1.6 Summary of the evidence**

3 **1.1.6.1 RQ1: Symptoms, signs, and early warning scores – evidence** 4 **statements**

5 **a) In people aged 16 years or over with suspected acute respiratory infection (ARI),** 6 **what are the symptoms, signs and early warning scores (EWS) that have been** 7 **evaluated?**

8 Several EWS have been evaluated in people aged 16 years or over with suspected ARI:
9 Centor, CRB-65, CURB-65, PSI, CREWS, NEWS, SIRS, SEWS, S-NEWS, ATS 2001,
10 IDSA/ATS 2007, SCAP/CURXO-80, SMART-COP and REA-ICU. Nine systematic reviews
11 addressed this research question; all assessed patients presenting in face-to-face settings
12 (primary care, walk-in medical centre, emergency department, acute medical unit or nursing
13 home) rather than remote settings. The most commonly assessed EWS were the PSI, CRB-
14 65 and CURB-65.

15 **b) In people aged 16 years or over with suspected acute respiratory infection (ARI),** 16 **what are the strategies for the triage of patients (for example, applying clinical** 17 **prediction rules using symptoms, signs, EWS thresholds) to avoid serious illness?**

18 The evidence was insufficient to definitively answer this question.

19 Seven systematic reviews assessed EWS for predicting mortality and/or to determine the site
20 of treatment for patients with community acquired pneumonia. There was a great deal of
21 overlap in the primary studies included in the reviews and many of the primary studies were
22 considered to have significant limitations.

23 Two reviews that assessed the CRB-65 (both good quality) concluded that further research is
24 needed in community settings. One of these reviews also assessed the PSI; however, the
25 PSI requires data from a large number of tests, some of which are not routinely conducted in
26 community settings. One review (also good quality) concluded that NEWS appears to
27 provide the most accurate score for predicting mortality and the need for ICU admission in
28 patients with respiratory distress in an emergency department or acute medical unit setting.

29 One review (good quality) concluded that individual symptoms and signs (absence of cough,
30 fever, anterior cervical adenopathy, tender anterior cervical adenopathy, any exudates) have
31 only a modest ability to rule in or out a diagnosis of streptococcal pharyngitis in adults
32 presenting to primary care or the emergency department with sore throat. The review
33 concluded that the Centor score (cut-off ≥ 3) has reasonably good specificity and can
34 enhance the appropriate prescribing of antibiotics for streptococcal pharyngitis, but that it
35 should be used with caution in low prevalence settings, such as primary care.

36 Only one review (good quality) assessed the use of EWS (PSI and two other scores) for
37 predicting mortality in nursing home residents with nursing home acquired pneumonia; the
38 review concluded that there are numerous problems with using the scores in clinical practice.

39 The review of economic evidence identified a single study which indicated that clinical scores
40 may be a cost-effective approach to triage patients compared with delayed prescribing. The
41 study also offers insight into the cost-effectiveness of diagnostic testing in ARI scenarios. In
42 this particular case, the findings indicated that there is no apparent advantage in
43 incorporating diagnostic testing alongside clinical scores compared to using clinical scores
44 alone. It is unclear whether the results obtained from managing a short-term condition (sore
45 throat) are generalisable to the broader assessment of other ARI conditions.

1 **1.1.6.2 RQ2: Different near-patient, rapid microbiological or biomarker tests –**

2 **What is the clinical effectiveness and cost effectiveness of different near-patient, rapid**
 3 **microbiological or biomarker tests alone or in combination to guide initial assessment**
 4 **and management in people aged 16 and over with suspected ARI?**

5 **GRADE summary table**

6 **Table 13: C-reactive POCT versus usual care in adults with suspected ARI**

No of studies (design)	Summary of findings			Quality ^o
	No of patients		Effect	
	CRP	Usual care	Result (95%CI)	
Hospital admission immediately after triage				
NR				
Hospital admission at 3 weeks to 6 months				
1 cluster-RCT ^a	0/49	0/38	Not reported	VERY LOW
1 cluster-RCT ^b	2/33	1/18	RR 1.09 (95% CI 0.11, 11.22)	VERY LOW
1 cluster-RCT ^c	0/65	0/59	Not reported	VERY LOW
1 cluster-RCT ^d	5/583	1/478	RR 4.10 (95% CI 0.48, 34.97)	VERY LOW
1 RCT ^e	35/304	34/301	RR 1.02 (95% CI 0.65, 1.59)	VERY LOW
1 RCT ^f	0/129	0/129	Not reported	VERY LOW
Escalation of care: re-consultation/appointment				
3 cluster-RCTs/1 RCT ^k	180/695	103/738	RR 1.61 (95% CI 1.07, 2.41)	VERY LOW
Escalation of care: virtual ward				
NR				
Escalation of care: emergency department visit				
NR				
Escalation of care: unplanned hospital admission				
NR				
Mortality at 7 days				
NR				
Mortality at 28 days				
1 cluster-RCT ^b	1/33	0/19	RR 1.68 (95% CI 0.07, 39.16)	VERY LOW
1 cluster-RCT ^c	0/65	0/59	Not reported	VERY LOW
1 cluster-RCT ^d	0/583	0/478	Not reported	VERY LOW
1 RCT ^e	0/325	2/324	RR 0.20 (95% CI 0.01, 4.14)	VERY LOW
1 RCT ^f	0/129	0/129	Not reported	VERY LOW
1 RCT ^h	0/507	0/501	Not reported	VERY LOW

^a Andreeva 2014.

^b Boere 2021.

^b Cals 2009.

^d Little 2013.

^e Butler 2019.

7
8
9
10
11

1
2
3
4
5
6
7
8
9
10
11
12

^f Cals 2010.
^g Very serious limitations due to uncertainties around selection bias and high risk of bias due to lack of blinding.
^h Very serious limitations due to uncertainties around selection bias and high risk of bias due to lack of blinding and incomplete outcome data reporting.
ⁱ Very serious imprecision because the 95% CI for the RR crosses 0.8 and 1.25.
^j Serious indirectness as test(s) not currently available in the UK.
^k Andreeva 2014,²⁹ Cals 2009,²⁶ Little 2013²⁵ and Cals 2010.²⁸
^l Serious inconsistency due to moderate heterogeneity ($I^2=56.6\%$).
^m Serious imprecision because the 95% CI for the RR crosses 1.25.
ⁿ Do 2016.³³
^o The overall quality of evidence for each outcome was downgraded to low for any serious factors and to very low for any very serious factors in the quality of evidence.

13 **Table 14: Procalcitonin POCT versus usual care in adults with suspected ARI**

No of studies (design)	Summary of findings			Quality ^e
	No of patients		Effect	
	Procalcitonin	Usual care	Result (95%CI)	
Hospital admission immediately after triage				
NR				
Hospital admission at 28 days				
NR				
Escalation of care: re-consultation/appointment				
1 cluster-RCT ^a	53/195	33/122	RR 1.00 (95% CI 0.69, 1.46)	VERY LOW
Escalation of care: virtual ward				
NR				
Escalation of care: emergency department visit				
NR				
Escalation of care: unplanned hospital admission				
NR				
Mortality at 7 days				
1 cluster-RCT ^a	0/163	0/114	Not reported	VERY LOW
Mortality at 28 days				
1 cluster-RCT ^a	0/163	0/114	Not reported	VERY LOW
Abbreviations: CI – confidence interval; CRP – C-reactive protein; NR – not reported; RCT – randomised controlled trial; RR – relative risk.				

14
15
16
17
18
19

^a Lhopitallier 2021
^b Very serious limitations due to lack of blinding and unclear allocation concealment.
^c Very serious limitations due to lack of blinding, unclear allocation concealment and incomplete outcome data.
^d Very serious imprecision because the 95% CI for the RR crosses 0.8 and 1.25.
^e The overall quality of evidence for each outcome was downgraded to low for any serious factors and to very low for any very serious factors in the quality of evidence.

1 **1.1.6.3 RQ3: Accuracy of near-patient, rapid tests to distinguish between bacterial and viral infection in suspected ARI**
 2 **What is the diagnostic accuracy of near-patient, rapid tests to distinguish between bacterial and viral infection in suspected**
 3 **acute respiratory infection?**

4 **Table 15: Symptoms and signs for the diagnosis of bacterial pneumonia**

Index test	Source of data	No. of included studies (participants)	Outcome	Result (95% CI)	Certainty of the body of evidence	Interpretation of effect
Individual symptoms and signs						
Cough	Gentilotti 2022	13 (8423)	Sensitivity	89.1% (66.4 to 97.1)	VERY LOW ¹	Cough may have adequate sensitivity, but the evidence was uncertain. Many people with bacterial pneumonia may have a cough.
			Specificity	13.4% (2.5 to 48.4)	MODERATE ²	Cough probably has poor specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will also have a cough.
Sputum production	Gentilotti 2022	7 (6392)	Sensitivity	63.9% (40.5 to 82.1)	LOW ³	Sputum production may have inadequate sensitivity. Many people with bacterial pneumonia may not have productive sputum.
			Specificity	45.3% (25.9 to 66.3)	MODERATE ²	Sputum production probably has poor specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will still have productive sputum.
Discoloured sputum	Gentilotti 2022	9 (3014)	Sensitivity	54.0% (39.8 to 67.7)	MODERATE ²	Discoloured sputum probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have discoloured sputum.

			Specificity	53.0% (39.0 to 66.5)	MODERATE ²	Discoloured sputum probably has poor specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will have discoloured sputum.
Purulent sputum (to detect bacterial exacerbations in people with COPD)	Pazmany 2021	3 (259)	Sensitivity	71% (42 to 90)	VERY LOW ⁴	Purulent sputum may have inadequate sensitivity to detect bacterial exacerbations of COPD, but the evidence was uncertain. Many people with bacterial exacerbations of COPD may not have purulent sputum.
			Specificity	51% (30 to 73)	MODERATE ⁵	Purulent sputum probably has poor specificity to detect bacterial exacerbations of COPD. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial exacerbations of COPD will still have productive sputum.
Chest pain	Gentilotti 2022	15 (8161)	Sensitivity	33.9% (21.5 to 49.0)	MODERATE ²	Chest pain probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have chest pain.
			Specificity	73.0% (61.7 to 81.9)	LOW ³	Chest pain may have inadequate specificity. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may still have chest pain.
Dyspnoea	Gentilotti 2022	14 (6215)	Sensitivity	62.6% (53.3 to 71.1)	MODERATE ²	Dyspnoea probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have dyspnoea.
			Specificity	45.5% (32.1 to 59.5)	MODERATE ²	Dyspnoea probably has inadequate specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will still have dyspnoea.
Sore throat	Gentilotti 2022	5 (1096)	Sensitivity	32.6% (20.2 to 48.0)	MODERATE ²	Sore throat probably has inadequate sensitivity. It is likely that many people with

						bacterial pneumonia will not have a sore throat.
			Specificity	45.1% (33.1 to 57.6)	MODERATE ²	Sore throat probably has inadequate specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will still have a sore throat.
Runny nose	Gentilotti 2022	7 (4630)	Sensitivity	45.3% (37.3 to 53.4)	MODERATE ²	Runny nose probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have a runny nose.
			Specificity	41.8% (28.1 to 56.8)	MODERATE ²	Runny nose probably has inadequate specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will still have a runny nose.
Myalgia	Gentilotti 2022	6 (1430)	Sensitivity	41.6% (19.0 to 68.5)	MODERATE ²	Myalgia probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have myalgia.
			Specificity	61.2% (40.7 to 78.4)	LOW ³	Myalgia may have inadequate specificity. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may still have myalgia.
Chill	Gentilotti 2022	8 (1933)	Sensitivity	45.7% (31.5 to 60.8)	MODERATE ²	Chills probably have inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have a chill.
			Specificity	60.2% (48.5 to 70.8)	MODERATE ²	Chills probably have inadequate specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will still have chills.
Diarrhoea	Gentilotti 2022	5 (4268)	Sensitivity	10.8% (6.3 to 17.7)	MODERATE ²	Diarrhoea probably has inadequate sensitivity. It is likely that most people with bacterial pneumonia will not have diarrhoea.

			Specificity	89.5% (75.4 to 95.9)	LOW ³	Diarrhoea may have adequate specificity. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may not have diarrhoea.
Impaired consciousness	Gentilotti 2022	4 (3208)	Sensitivity	11.7% (9.3 to 14.5)	MODERATE ²	Impaired consciousness probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have impaired consciousness.
			Specificity	92.9% (90.5 to 94.7)	MODERATE ²	Impaired consciousness probably has high specificity. Among people with suspected acute respiratory infection, it is likely that most people who do not have bacterial pneumonia will not have impaired consciousness.
SpO ₂	Gentilotti 2022	6 (2821)	Sensitivity	22.8% (12.4 to 38.2)	MODERATE ²	Low oxygen saturations probably have inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have low oxygen saturations.
			Specificity	86.6% (80.7 to 90.9)	LOW ³	Low oxygen saturations may have adequate specificity. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may not have low oxygen saturations.
Fever >37.8°C	Gentilotti 2022	17 (11219)	Sensitivity	42.0% (26.7 to 58.9)	MODERATE ²	Fever probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have a fever.
			Specificity	80.4% (59.8 to 91.9)	VERY LOW ¹	Fever may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may also not have a fever.
Systolic BP	Gentilotti 2022	4 (3262)	Sensitivity	9.6% (2.8 to 28.3)	MODERATE ²	Low systolic blood pressure probably has inadequate sensitivity. It is likely that most

						people with bacterial pneumonia will not have a low systolic blood pressure.
			Specificity	95.0% (80.7 to 98.8)	LOW ³	Low systolic blood pressure may have high specificity. Among people with suspected acute respiratory infection, most people who do not have bacterial pneumonia may not have a low systolic blood pressure.
Tachycardia	Gentilotti 2022	11 (9474)	Sensitivity	27.2% (15.1 to 43.9)	MODERATE ²	Tachycardia probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have tachycardia.
			Specificity	84.2% (71.5 to 91.9)	VERY LOW ¹	Tachycardia may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may not have tachycardia.
Tachypnoea	Gentilotti 2022	12 (10351)	Sensitivity	27.9% (13.1 to 49.8)	MODERATE ²	Tachypnoea probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have tachypnoea.
			Specificity	80.2% (58.2 to 92.2)	VERY LOW ¹	Tachypnoea may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may not have tachypnoea.
Reduced breath sounds	Gentilotti 2022	4 (459)	Sensitivity	24.7% (8.3 to 54.4)	MODERATE ²	Reduced breath sounds probably have inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have reduced breath sounds.
			Specificity	89.0% (75.0 to 95.6)	LOW ³	Reduced breath sounds may have adequate specificity. Among people with suspected acute respiratory infection, many people who

						do not have bacterial pneumonia may not have reduced breath sounds.
Wheezing	Gentilotti 2022	6 (2403)	Sensitivity	17.3% (9.6 to 29.2)	MODERATE ²	Wheezing probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have wheeze.
			Specificity	86.4% (70.5 to 94.4)	VERY LOW ¹	Wheezing may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may not have wheeze.
Crackles	Gentilotti 2022	10 (6175)	Sensitivity	40.3% (23.6 to 59.7)	MODERATE ²	Presence of crackles on auscultation probably have inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have crackles.
			Specificity	83.1% (58.5 to 94.5)	VERY LOW ¹	Presence of crackles on auscultation may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may not have crackles.
Combinations of symptoms and signs						
Presence/absence of specific symptoms and signs	Schierenberg 2017	6 (not reported)	Area under the curve	Ranged from 53% to 79% depending on model used	VERY LOW ⁶	Combinations of signs and symptoms may not have adequate diagnostic accuracy to identify bacterial pneumonia, although this will vary according to the model used.
Combinations of symptoms and signs plus CRP measurement						
Predicted risk threshold 2.5%	Minnaard 2017	8 (5308)	Sensitivity	97% (95 to 98)	MODERATE ⁷	At a predicted risk threshold of 2.5%, clinical prediction models incorporating CRP probably have adequate sensitivity. It is likely that most people with bacterial pneumonia will have a predicted risk of >2.5%.
			Specificity	36% (34 to 37)	MODERATE ⁷	At a predicted risk threshold of 2.5%, clinical prediction models incorporating CRP probably have inadequate specificity. Among people with suspected acute respiratory

						infection, it is likely that many people who do not have bacterial pneumonia will also have a predicted risk >2.5%.
Predicted risk threshold 20%	Minnaard 2017	8 (5308)	Sensitivity	70% (66 to 73)	MODERATE ⁷	At a predicted risk threshold of 20%, clinical prediction models incorporating CRP probably have inadequate sensitivity. It is likely that many people with bacterial pneumonia will have a predicted risk <20%.
			Specificity	90% (89 to 91)	LOW ⁸	At a predicted risk threshold of 20%, clinical prediction models incorporating CRP may have high specificity. Among people with suspected acute respiratory infection, most people who do not have bacterial pneumonia may have a predicted risk <20%.

- 1 1 Downgraded by three levels due to a serious risk of bias and very serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 2 2 Downgraded by one level for a serious risk of bias. Note that inconsistency was not able to be assessed for this outcome.
- 3 3 Downgraded by two levels due to a serious risk of bias and serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 4 4 Downgraded by three levels for a serious risk of bias and very serious imprecision.
- 5 5 Downgraded by one level for a serious risk of bias.
- 6 6 Downgraded by one level for serious inconsistency, one level for serious imprecision and one level for publication bias, as authors were unable to access data from at least four publications for inclusion in their IPD meta-analysis.
- 7 7 Downgraded by one level for publication bias, as authors were unable to access data from at least four publications for inclusion in their IPD meta-analysis.
- 8 8 Downgraded by one level for publication bias (as authors were unable to access data from at least four publications for inclusion in their IPD meta-analysis) and downgraded by one level for serious imprecision.
- 9
- 10

11 **Table 16: Host biomarkers to detect bacterial or viral respiratory tract infection**

Index test	Source of data	No. of included studies (participants)	Outcome	Result (95% CI)	Certainty of the body of evidence	Interpretation of effect
CRP						
CRP >10mg/L	Gentilotti 2022	4 (944)	Sensitivity	92% (56 to 99)	VERY LOW ¹	CRP (>10mg/L) may have high sensitivity, but the evidence was uncertain. Most people with bacterial pneumonia may have a CRP level >10mg/L.

			Specificity	43% (22 to 66)	MODERATE ²	CRP (>10mg/L) probably has inadequate specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will have a CRP level >10mg/L.
CRP >20mg/L	Gentilotti 2022	5 (3531)	Sensitivity	83% (64 to 93)	VERY LOW ¹	CRP (>20mg/L) may have adequate sensitivity, but the evidence was uncertain. Many people with bacterial pneumonia may have a CRP level >20mg/L.
			Specificity	55% (37 to 73)	MODERATE ²	CRP (>20mg/L) probably has inadequate specificity. Among people with suspected acute respiratory infection, it is likely that many people who do not have bacterial pneumonia will have a CRP level >20mg/L.
CRP >20mg/L (primary care only, adults and children)	Gentilotti 2022	4 (3362)	Sensitivity	78% (57 to 90)	VERY LOW ³	CRP (>20mg/L) may have adequate sensitivity in a primary care setting, but the evidence was uncertain. Many people with bacterial pneumonia may have a CRP level >20mg/L.
			Specificity	58% (36 to 78)	VERY LOW ⁴	CRP (>20mg/L) probably has inadequate specificity in a primary care setting. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may have a CRP level >20mg/L.
CRP >50mg/L	Gentilotti 2022	5 (4219)	Sensitivity	77% (51 to 91)	VERY LOW ¹	CRP (>50mg/L) may have adequate sensitivity, but the evidence was uncertain. Many people with bacterial pneumonia may have a CRP level >50mg/L.
			Specificity	74% (51 to 88)	LOW ⁵	CRP (>50mg/L) may have inadequate specificity. Among people with

						suspected acute respiratory infection, many people who do not have bacterial pneumonia may have a CRP level >50mg/L.
CRP >100mg/L	Gentilotti 2022	6 (4418)	Sensitivity	52% (31 to 72)	MODERATE ²	CRP (>100mg/L) probably has inadequate sensitivity. It is likely that many people with bacterial pneumonia will not have a CRP level >100mg/L
			Specificity	91% (79 to 97)	LOW ⁵	CRP (>100mg/L) may have high specificity. Among people with suspected acute respiratory infection, most people who do not have bacterial pneumonia may have a CRP level ≤100mg/L.
Procalcitonin						
Procalcitonin >0.1 mcg/mL	Gentilotti 2022	4 (1092)	Sensitivity	74% (38 to 93)	VERY LOW ¹	Procalcitonin (>0.1mcg/mL) may have inadequate sensitivity, but the evidence was very uncertain. Many people with bacterial pneumonia may not have a procalcitonin level >0.1mcg/mL.
			Specificity	74% (36 to 94)	VERY LOW ¹	Procalcitonin (>0.1mcg/mL) may have inadequate specificity, but the evidence was very uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may have a procalcitonin level >0.1mcg/mL.
Procalcitonin >0.25 mcg/mL	Gentilotti 2022	5 (4019)	Sensitivity	44% (14 to 79)	LOW ⁵	Procalcitonin (>0.25mcg/mL) may have inadequate sensitivity. Many people with bacterial pneumonia may not have a procalcitonin level >0.25mcg/mL.
			Specificity	89% (50 to 98)	VERY LOW ¹	Procalcitonin (>0.25mcg/mL) may have adequate specificity. Among people with suspected acute respiratory infection, most people who do not have

						bacterial pneumonia may have a procalcitonin level ≤ 0.25 mcg/mL.
Procalcitonin >0.50 mcg/mL (adults and children)	Gentilotti 2022	4 (1195)	Sensitivity	44% (19 to 33)	LOW ⁶	Procalcitonin (>0.50mcg/mL) may have inadequate sensitivity. Many people with bacterial pneumonia may not have a procalcitonin level >0.50mcg/mL.
			Specificity	93% (43 to 100)	VERY LOW ³	Procalcitonin (>0.50mcg/mL) may have high specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, most people who do not have bacterial pneumonia may have a procalcitonin level ≤ 0.50 mcg/mL.
TRAIL, IP-10 and CRP (ImmunoXpert)						
TRAIL, IP-10 and CRP to diagnose bacterial infection (adults and children)	Carlton 2021	4 (1291)	Sensitivity	85% (75 to 91)	VERY LOW ⁷	ImmunoXpert may have adequate sensitivity, but the evidence was uncertain. Most people with bacterial pneumonia may have a positive (bacterial) result.
			Specificity	86% (73 to 93)	VERY LOW ⁸	ImmunoXpert may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia may have a negative (bacterial) result.
TRAIL, IP-10 and CRP to diagnose viral infection (adults and children)	Carlton 2021	3 (989)	Sensitivity	90% (79 to 96)	VERY LOW ⁹	ImmunoXpert may have high sensitivity, but the evidence was uncertain. Most people with viral infection may have a positive (viral) result.
			Specificity	92% (83 to 96)	VERY LOW ⁷	ImmunoXpert may have high specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have

						a viral infection may have a negative (viral) result.
CRP and MxA (FebriDx)						
CRP and MxA to diagnose bacterial infection (adults and children)	Carlton 2021	4 (598)	Sensitivity	84% (75 to 90)	LOW ¹⁰	FebriDx may have adequate sensitivity. Many people with bacterial pneumonia may have a positive (bacterial) result.
			Specificity	93% (90 to 95)	MODERATE ¹¹	FebriDx probably has high specificity. Among people with suspected acute respiratory infection, it is likely that most people who do not have bacterial pneumonia will have a negative (bacterial) result.
CRP and MxA to diagnose viral infection (adults and children)	Carlton 2021	4 (583)	Sensitivity	87% (72 to 95)	VERY LOW ¹²	FebriDx may have adequate sensitivity, but the evidence was uncertain. Many people with viral infection may have a positive (viral) result.
			Specificity	82% (66 to 86)	LOW ¹⁰	FebriDx may have adequate specificity. Among people with suspected acute respiratory infection, many people who do not have a viral infection may have a negative (viral) result.
White cell differential count						
White cell count to diagnose pneumonia	Castro-Guardiola 2000, Holm 2007, Liu 2013	3 (1148)	2 studies reported sensitivity estimates ranging from 10.1 to 71.1%, and specificity estimates ranging from 31.3 to 94.6%, depending on the threshold used. 1 study reported an area under the curve of 0.65.		VERY LOW ¹³	The evidence regarding the diagnostic accuracy of white cell counts to diagnose bacterial respiratory infection was very uncertain.
White cell count to diagnose bacterial pharyngitis	Gulich 1999	1 (179)	Area under the curve	0.68 (no confidence intervals)	LOW ¹⁴	White cell count may have inadequate diagnostic accuracy to diagnose bacterial pharyngitis.
Other host biomarkers						

CRP and neopterin to diagnose bacterial infection	Carlton 2021	1 (198)	Sensitivity	80% (71 to 86)	VERY LOW ¹⁵	CRP and neopterin may have adequate sensitivity, but the evidence was uncertain. Many people with bacterial pneumonia may have an elevated CRP/neopterin level.
			Specificity	82% (71 to 89)	VERY LOW ¹⁵	CRP and neopterin may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, many people who do not have bacterial pneumonia will not have an elevated CRP/neopterin level.

- 1 Downgraded by one level for serious risk of bias, and by two levels for very serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 2 Downgraded by one level for serious risk of bias. Note that inconsistency was not able to be assessed for this outcome.
- 3 Downgraded by one level for serious risk of bias, one level for indirectness (as adults and children were included) and by two levels for very serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 4 Downgraded by one level for serious risk of bias, one level for indirectness (as adults and children were included) and by one level for serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 5 Downgraded by one level for serious risk of bias, and by one level for serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 6 Downgraded by one level for serious risk of bias and one level for indirectness (as adults and children were included). Note that inconsistency was not able to be assessed for this outcome.
- 7 Downgraded by one level for serious risk of bias, one level for indirectness (as adults and children were included) and by one level for serious imprecision.
- 8 Downgraded by one level for serious risk of bias, one level for indirectness (as adults and children were included) and by two levels for very serious imprecision.
- 9 Downgraded by one level for serious risk of bias, one level for indirectness (as adults and children were included), one level for inconsistency and by one level for serious imprecision.
- 10 Downgraded by one level for serious indirectness (as adults and children were included) and one level for serious imprecision.
- 11 Downgraded by one level for serious indirectness (as adults and children were included).
- 12 Downgraded by one level for serious indirectness (as adults and children were included) and two levels for very serious imprecision.
- 13 Downgraded by one level for serious risk of bias, one level for indirectness (as all index tests were carried out in a laboratory setting, not actually at point of care), one level for inconsistency and by two levels for very serious imprecision (only a narrative synthesis was possible, and estimates from individual studies varied considerably).
- 14 Downgraded by one level for indirectness (as the index test was carried out in a laboratory setting, not actually at point of care) and by one level for serious imprecision (no confidence intervals were reported)
- 15 Downgraded by one level for serious risk of bias, one level for indirectness (as neopterin tests were carried out in a laboratory setting, not actually at point of care), and by one level for serious imprecision.

21 **Table 17: Single pathogen tests for influenza and RSV**

Index test	Source of data	No. of included studies (participants)	Outcome	Result (95% CI)	Certainty of the body of evidence	Interpretation of effect
------------	----------------	--	---------	-----------------	-----------------------------------	--------------------------

Single pathogen tests for influenza						
Immunochromatography	Gentilot ti 2022	15 (2897)	Sensitivity	65% (47 to 79)	LOW ¹	Immunochromatography tests may have inadequate sensitivity. Many people with influenza may not have a positive test.
			Specificity	96% (92 to 98)	MODERATE ²	Immunochromatography tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without influenza will have a negative test.
Immunochromatography (adults and children, primary care only)	Gentilot ti 2022	11 (3351)	Sensitivity	56% (36 to 74)	LOW ³	Immunochromatography tests may have inadequate sensitivity in a primary care setting. Many people with influenza may not have a positive test.
			Specificity	95% (89 to 98)	VERY LOW ⁴	Immunochromatography tests may have high specificity in a primary care setting, but the evidence was uncertain. Among people with suspected acute respiratory infection, most people without influenza may have a negative test.
Immunochromatography (adults and children, emergency department only)	Gentilot ti 2022	25 (15021)	Sensitivity	71% (60 to 80)	LOW ⁵	Immunochromatography tests may have inadequate sensitivity in an emergency department setting. Many people with influenza may not have a positive test.
			Specificity	98% (96 to 99)	MODERATE ⁶	Immunochromatography tests probably have high specificity in an emergency department setting. Among people with suspected acute respiratory infection, it is likely that most people without influenza will have a negative test.
Immunochromatography (adults and children, outpatient department only)	Gentilot ti 2022	17 (6110)	Sensitivity	66% (55 to 76)	LOW ⁵	Immunochromatography tests may have inadequate sensitivity in an outpatient setting. Many people with influenza may not have a positive test.
			Specificity	97% (93 to 99)	MODERATE ⁶	Immunochromatography tests probably have high specificity in an outpatient setting. Among people with suspected acute respiratory infection, it is likely that most people without influenza will have a negative test.
Direct immunofluorescence	Gentilot ti 2022	19 (7635)	Sensitivity	78% (67 to 86)	VERY LOW ⁴	Direct immunofluorescence may have adequate sensitivity, but the evidence was very uncertain. Many people with influenza may have a positive test.

(adults and children)			Specificity	95% (90 to 98)	LOW ³	Direct immunofluorescence tests may have high specificity. Among people with suspected acute respiratory infection, most people without influenza may have a negative test.
Direct immunofluorescence (adults and children, emergency department only)	Gentilotti 2022	5 (1314)	Sensitivity	82% (72 to 89)	VERY LOW ⁴	Direct immunofluorescence may have adequate sensitivity in an emergency department setting, but the evidence was very uncertain. Many people with influenza may have a positive test.
			Specificity	96% (93 to 97)	LOW ³	Direct immunofluorescence tests may have high specificity in an emergency department setting. Among people with suspected acute respiratory infection, most people without influenza may have a negative test.
Optical immunoassay (adults and children)	Gentilotti 2022	9 (3910)	Sensitivity	68% (51 to 81)	VERY LOW ⁴	Optical immunoassays may have inadequate sensitivity, but the evidence was very uncertain. Many people with influenza may not have a positive test.
			Specificity	88% (81 to 93)	VERY LOW ⁴	Optical immunoassays may have adequate specificity, but the evidence was very uncertain. Among people with suspected acute respiratory infection, many people without influenza may have a negative test.
MariPOC test (adults and children)	Gentilotti 2022	5 (1231)	Sensitivity	78% (61 to 89)	VERY LOW ⁴	MariPOC tests may have adequate sensitivity, but the evidence was very uncertain. Many people with influenza may have a positive test.
			Specificity	99% (97 to 99)	LOW ³	MariPOC tests may have high specificity. Among people with suspected acute respiratory infection, most people without influenza may have a negative test.
Chemiluminescent neuraminidase assay (adults and children)	Gentilotti 2022	4 (787)	Sensitivity	81% (51 to 94)	VERY LOW ⁷	Chemiluminescent neuraminidase assays may have adequate sensitivity, but the evidence was uncertain. Many people with influenza may have a positive test.
			Specificity	82% (65 to 91)	VERY LOW ⁷	Chemiluminescent neuraminidase assays may have adequate specificity, but the evidence was uncertain. Among people with suspected acute respiratory

						infection, many people without influenza may have a negative test.
Nucleic acid amplification tests: standalone, single pathogen PCR (adults and children)	Gentilot ti 2022	30 (25027)	Sensitivity	95.1% (89.3 to 97.8)	VERY LOW ⁴	Single pathogen PCR tests may have high sensitivity, but the evidence was uncertain. Most people with influenza may have a positive test.
			Specificity	97.5% (95.5 to 98.7)	LOW ³	Single pathogen PCR tests may have high specificity. Among people with suspected acute respiratory infection, most people without influenza may have a negative test.
Nucleic acid amplification tests: non-PCR based (adults and children)	Gentilot ti 2022	23 (4863)	Sensitivity	92% (88 to 94)	VERY LOW ⁴	Non-PCR based nucleic acid amplification tests may have high sensitivity, but the evidence was uncertain. Most people with influenza may have a positive test.
			Specificity	98% (95 to 99)	LOW ³	Non-PCR based nucleic acid amplification tests may have high specificity. Among people with suspected acute respiratory infection, most people without influenza may have a negative test.
Nucleic acid amplification tests: non-PCR based (adults and children, emergency department only)	Gentilot ti 2022	14 (3138)	Sensitivity	91% (87 to 94)	VERY LOW ⁴	Non-PCR based nucleic acid amplification tests may have high sensitivity in an emergency department setting, but the evidence was uncertain. Most people with influenza may have a positive test.
			Specificity	98% (95 to 99)	LOW ³	Non-PCR based nucleic acid amplification tests may have high specificity in an emergency department setting. Among people with suspected acute respiratory infection, most people without influenza may have a negative test.
Single pathogen tests for RSV						
Direct immunofluorescence	Onwuc hekwa 2023	1 (49)	Sensitivity	56% (31 to 78)	VERY LOW ⁸	Direct immunofluorescence may have inadequate sensitivity, but the evidence was uncertain. Many people who have RSV may not have a positive test.
			Specificity	100% (89 to 100)	VERY LOW ⁸	Direct immunofluorescence may have high specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, most people without RSV may have a negative test.

Rapid antigen test	Onwuchekwa 2023	1 (281)	Sensitivity	18% (12 to 27)	LOW ⁹	Rapid antigen tests may have inadequate sensitivity. Most people who have RSV may not have a positive test.
			Specificity	98% (86 to 100)	VERY LOW ¹⁰	Rapid antigen tests may have high specificity, but the evidence was uncertain. Among people with suspected acute respiratory infection, most people without RSV may have a negative test.

- 1 Downgraded by one level for serious risk of bias and one level for serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 2 Downgraded by one level for serious risk of bias. Note that inconsistency was not able to be assessed for this outcome.
- 3 Downgraded by one level for serious risk of bias and one level for indirectness (as adults and children were included). Note that inconsistency was not able to be assessed for this outcome.
- 4 Downgraded by one level for serious risk of bias, one level for indirectness (as adults and children were included), and one level for serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 5 Downgraded by one level for serious indirectness and one level for serious imprecision.
- 6 Downgraded by one level for serious indirectness.
- 7 Downgraded by one level for serious risk of bias, one level for indirectness (as adults and children were included), and two levels for very serious imprecision. Note that inconsistency was not able to be assessed for this outcome.
- 8 Downgraded by two levels for imprecision due to wide confidence intervals and very small sample size, and one level for indirectness (as unclear whether this test was suitable for use at point of care).
- 9 Downgraded by one level for risk of bias and one level for indirectness (as this study included some retrospective [frozen] samples, and may have included hospitalised participants).
- 10 Downgraded by one level for risk of bias, one level for indirectness (as this study included some retrospective [frozen] samples, and may have included hospitalised participants) and one level for serious imprecision.

14 **Table 18: Multiplex PCR for diagnosis of influenza and RSV**

Index tests	Source of data	No. of included studies (participants)	Outcome	Result (95% CI)	Certainty of the body of evidence	Interpretation of effect
RSV						
All multiplex PCR tests for RSV	Farfour 2022, Morris 2021, Yin 2022, Youngs 2019,	5 studies (2273)	Sensitivity	84.9% (73.5 to 91.9)	VERY LOW ¹	Multiplex PCR tests may have adequate sensitivity, but the evidence was uncertain. Most people with RSV may have a positive test.
			Specificity	99.5% (99.1 to 99.7)	MODERATE ²	Multiplex PCR tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without RSV will have a negative test.

	Zuurbie r 2022					
Cobas Liat tests for RSV	Yin 2022, Youngs 2019	2 studies (965)	Sensitivity	86.7% (59.5 to 96.6)	VERY LOW ¹	Cobas Liat tests may have adequate sensitivity, but the evidence was uncertain. Most people with RSV may have a positive test.
			Specificity	99.3% (98.5 to 99.6)	MODERATE ²	Cobas Liat tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without RSV will have a negative test.
Xpert Xpress tests for RSV	Morris 2021, Zuurbie r 2022	2 studies (1109)	Sensitivity	84.5% (69.4 to 92.9)	VERY LOW ¹	Xpert Xpress tests may have adequate sensitivity, but the evidence was uncertain. Most people with RSV may have a positive test.
			Specificity	99.6% (99.0 to 99.9)	MODERATE ²	Xpert Xpress tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without RSV will have a negative test.
Influenza A						
All multiplex PCR tests for influenza A	Escarata 2022, Farfour 2022, Morris 2021, Maignan 2016, Valentin 2019 (two tests included), Yin 2022, Youngs 2019.	8 studies (2212)	Sensitivity	98.2% (90.7 to 99.7)	LOW ³	Multiplex PCR tests may have high sensitivity. Most people with influenza A may have a positive test.
			Specificity	98.6% (96.6 to 99.4)	LOW ³	Multiplex PCR tests may have high specificity. Among people with suspected acute respiratory infection, most people without influenza A may have a negative test.

Cobas Liat tests for influenza A	Maignan 2016, Valentin 2019, Yin 2022, Youngs 2019.	4 studies (1259)	Sensitivity	99.8% (18.8 to 100)	VERY LOW ⁴	Cobas Liat tests may have high sensitivity, but the evidence was uncertain. Most people with influenza A may have a positive test.
			Specificity	97.9 (94.0 to 99.3)	MODERATE ⁵	Cobas Liat tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without influenza A will have a negative test.
Xpert Xpress tests for influenza A	Escarate 2022, Morris 2021, Valentin 2019.	3 studies (754)	Sensitivity	97.0% (92.9 to 98.7)	MODERATE ²	Xpert Xpress tests probably have adequate sensitivity. It is likely that most people with influenza A will have a positive test.
			Specificity	98.5% (96.2 to 99.4)	MODERATE ²	Xpert Xpress tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without influenza A will have a negative test.
Influenza B						
All multiplex PCR tests for influenza B	Escarate 2022, Maignan 2016, Valentin 2019 (two tests included), Yin 2022, Youngs 2019.	6 studies (1823)	Sensitivity	94.5% (88.6 to 97.5)	VERY LOW ⁶	Multiplex PCR tests may have high sensitivity, but the evidence was uncertain. Most people with influenza B may have a positive test.
			Specificity	99.1 (98.1 to 99.6)	LOW ³	Multiplex PCR tests may have high specificity. Among people with suspected acute respiratory infection, most people without influenza B may have a negative test.
Cobas Liat tests for influenza B	Maignan 2016, Valentin 2019, Yin 2022,	4 studies (1420)	Sensitivity	92.9% (84.3 to 96.9)	LOW ⁶	Cobas Liat tests may have high sensitivity. Most people with influenza B may have a positive test.
			Specificity	99.0% (97.6 to 99.6)	MODERATE ⁵	Cobas Liat tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without influenza B will have a negative test.

	Youngs 2019.					
Xpert Xpress tests for influenza B	Escarate 2022, Valentin 2019.	2 studies (403)	Sensitivity	96.4% (90.7 to 99.0)	MODERATE ²	Xpert Xpress tests probably have high sensitivity. It is likely that most people with influenza B will have a positive test.
			Specificity	99.4% (97.4 to 99.8)	MODERATE ²	Xpert Xpress tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without influenza B will have a negative test.
Influenza A and/or B						
All multiplex PCR tests for influenza A/B	Boku 2013, Escarate 2022, Hansen 2018, Maignan 2016, Valentin 2019 (two tests included), Yin 2022, Youngs 2019.	8 studies (2162)	Sensitivity	97.4% (92.9 to 99.0)	LOW ³	Multiplex PCR tests may have high sensitivity. Most people with influenza A/B may have a positive test.
			Specificity	97.0% (94.5 to 98.4)	LOW ³	Multiplex PCR tests may have high specificity. Among people with suspected acute respiratory infection, most people without influenza A/B may have a negative test.
Cobas Liat tests for influenza A/B	Hansen 2018, Maignan 2016, Valentin 2019, Yin 2022,	5 studies (1712)	Sensitivity	97.1% (88.6 to 99.3)	LOW ⁶	Cobas Liat tests may have high sensitivity. Most people with influenza A/B may have a positive test.
			Specificity	96.8% (93.2 to 98.5)	MODERATE ⁵	Cobas Liat tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without influenza A/B will have a negative test.

	Youngs 2019.					
Xpert Xpress tests for influenza A/B	Escarate 2022, Valentin 2019	2 studies (403)	Sensitivity	97.5% (93.6 to 99.1)	MODERATE ²	Xpert Xpress tests probably have high sensitivity. It is likely that most people with influenza A/B will have a positive test.
			Specificity	97.5% (94.5 to 98.9)	MODERATE ²	Xpert Xpress tests probably have high specificity. Among people with suspected acute respiratory infection, it is likely that most people without influenza A/B will have a negative test.

- 1 Downgraded by one level for serious risk of bias and by two levels for very serious imprecision.
- 2 Downgraded by one level for serious risk of bias.
- 3 Downgraded by one level for serious risk of bias and by one level for serious inconsistency (due to a wide prediction region and relatively large tau2).
- 4 Downgraded by one level for serious inconsistency (due to a wide prediction region and relatively large tau2) and by two levels for very serious imprecision.
- 5 Downgraded by one level for serious inconsistency (due to a wide prediction region and relatively large tau2).
- 6 Downgraded by one level for serious inconsistency (due to a wide prediction region and relatively large tau2) and by one level for serious imprecision.
- 7 Downgraded by one level for risk of bias, by one level for serious inconsistency (due to a wide prediction region and relatively large tau2) and by one level for serious imprecision.

10 See appendices of [individual reviews](#) for full GRADE tables.

11

1 **1.1.7 Economic evidence**

2 **1.1.7.1 Included studies**

3 See [individual reviews](#) for details of the searches and the number of studies identified at
4 each stage of sifting. 1 study was identified for review question 1, and 8 studies were
5 identified for review question 2. A review of the economic evidence was not undertaken for
6 review question 3, due to the overlap with review question 2.

7 A study selection summary is presented as a PRISMA diagram in an appendix in each
8 review.

9 Full references of the included studies can be found in each review.

10 **1.1.7.2 Excluded studies**

11 Details of studies excluded at full text, along with reasons for exclusion are given in an
12 appendix of each review.

13 **1.1.8 Summary of included economic evidence**

14 The summaries of studies tables are presented below for each of the evidence reviews.
15 Fuller details are included in each [evidence review](#).

1 **Table 19: RQ1: Symptoms, signs, and early warning scores – included economic studies**

Study details	Applicability and limitations	Other comments	Costs	Effects	ICER	Uncertainty
Little (2014)	Partially applicable Minor limitations. This study is only partially relevant to the review question, but highlights the possible impact of using symptoms to assess short term ARI conditions.	<ul style="list-style-type: none"> • UK NHS setting • Cost-utility analysis • Cost-effectiveness analysis • Population: Patients aged ≥ 3 years and had acute sore throat • Comparators: <ol style="list-style-type: none"> 1. Clinical scores (FeverPAIN) 2. Rapid antigen detection tests (RADTs) 3. Delayed antibiotic prescribing (DP) 	Total costs at 14 and 28-days (95% CI): - DP: £49.70 (43.30 to 56.00) - FeverPAIN: £45.90 (41.50 to 50.20) - RADT: £48.50 (45.00 to 52.00)	QALYs in 14-day period (95% CI (CI)): - DP: 0.0057 (0.0044 to 0.007) - FeverPAIN: 0.0058 (0.0045 to 0.0071) - RADT: 0.00584 (0.0046 to 0.0071) QALYs in 28-day period (95% CI): - DP: 0.0171 (0.0131 to 0.0211) - FeverPAIN: 0.01741 (0.0135 to 0.0213) - RADT: 0.01752 (0.0138 to 0.0212) Symptom score - DP: 3.15 (2.93 to 3.37) - FeverPAIN: 2.83 (2.61 to 3.05) - RADT: 2.84 (2.62 to 3.07)	Cost-utility analysis: -DP is dominated (more costly and less clinically effective) by FeverPAIN and RADT. -Compared to FeverPain, RADT generates an ICER of £74,286 and £24,528 at 14 and 28 days respectively. Cost-effectiveness analysis: -DP is dominated (more costly and less clinically effective) by FeverPAIN and RADT. -RADT is dominated (more costly and less clinically effective) by FeverPAIN	Cost-effectiveness acceptability curves indicated considerable uncertainty, particularly around the QALY estimate. At a threshold of £30,000 per QALY, the probabilities that delayed prescribing, clinical score and RADT are the most cost-effective option were 25%, 40% and 35% respectively, for the 14-day period, and 28%, 38% and 35%, respectively, for the 28-day period.

Abbreviations: CI = confidence interval; DP = delayed antibiotic prescribing; ICER = incremental cost effectiveness ratio; QALY = quality adjusted life years; RADT = rapid antigen detection test.

1 **Table 20: RQ2: Different near-patient, rapid microbiological or biomarker tests – included economic studies**

Study details	Applicability	Other comments	Costs	Effects	ICER	Uncertainty
C-reactive protein tests						
Holmes (2018)	Directly applicable	Adult patients; symptoms of ARI for >12 hours Alere Afinion AS100 CRP POCT UK NHS perspective.	Costs per patient Pragmatic use of testing: Test £52.35 No test £40.41 Adhering to guidelines: Test £48.79 No test £39.48	QALYs per patient Pragmatic use of testing: Test 0.0615 No test 0.0609 Adhering to guidelines: Test 0.0577 No test 0.0556	Pragmatic use of testing: £19,705 Adhering to guidelines: £4,390	<i>Pragmatic use of testing</i> The probability that test is cost-effective at £20,000 per QALY threshold is 49.06%, and 62.82% at £30,000 per QALY threshold. <i>Adhering to guidelines</i> Probability test is cost-effective at £20,000/QALY threshold is 84.10%, and 86.33% at £30,000. If the test cost 18p more, or test use fell by 5%, the ICER exceeds £20,000. Test results in higher utility but at a higher cost in 75% of simulations.
Hunter (2015)	Directly applicable	Adult patients attending primary care with RTI symptoms Afinion Analyzer CRP POCT by GP; CRP	Cost per 100 patients GP+CRP: £18,039 Nurse+CRP: £17,401 GP+CRP+training: £18,431	QALYs per 100 patients GP+CRP: 255.764 Nurse+CRP: 255.761	GP+CRP and nurse+CRP are dominant over current practice.	GP+CRP is dominant compared to current practice in 50% of simulations, in 65% the nurse+CRP is dominant and in 19% the

		POCT by nurse; CRP POCT by GP+ communication training for GP UK NHS perspective, primary care	No test: £18,081	GP+CRP+training: 255.588 No test: 255.630		GP+CRP+training is dominant. Nurse+CRP has the highest NMB in CEAC. Changing most model parameters has little impact on conclusions.
Oppong (2013)	Partially applicable Conducted in Sweden and Norway but used a health service perspective	Patients aged ≥18 years; presenting to GP with acute or worsened cough as the main symptom for up to 28 days, or suspected LRTI CRP POCT UK NHS perspective, primary care	Test increases healthcare costs by €11.27 per patient	QALY gain of 0.0012 with test per patient	€9,391	At a WTP threshold of €30,000, the probability of POC CRP being cost-effective is approximately 70%.
Francis (2020)	Directly applicable	Bacterial exacerbation of COPD Alere Afinion CRP POCT UK NHS perspective	Costs per patient: Test: £759.35 No test: £629.72	QALYs per patient: Test: 0.3 No test: 0.2915	£15,251	Results remained reasonably robust when cost inputs were changed but were sensitive to changes in QALY inputs. The ICER would reduce to £1,054 if COPD-related costs only were included. Most results found CRP POCT to be more costly but more effective. The CUA (using imputation

						and an ITT approach) gave an ICER of £14,334.
Group A Streptococcus tests (including Group C/G)						
Fraser (2020)	Directly applicable	Adults and children who present with an acute sore throat Group A streptococcus (GAS) POCT (14 tests evaluated) in conjunction with clinical scoring tools e.g. Centor and FeverPAIN score for strep A UK NHS and Personal Social Services.	Costs per 1000 patients in primary care: NADAL Strep A–test (cheapest test): £54,394 Cobas Liat Strep A Assay (most expensive test): £71,277 No test: £49,147 Costs per 1000 patients in secondary care: NADAL Strep A–test (cheapest test): £49,318 Cobas Liat Strep A Assay (most expensive): £65,186 No test £49,147	QALYs per 1000 patients in primary care: Abbott Clearview Exact Strep A cassette or test strip (lowest QALYs): 859.821 Cepheid’s Xpert Xpress Strep A test (highest QALYs): 895.829 No test: 859.825 QALYs per 1000 patients in secondary care: Abbott Clearview tests generated fewer QALYs than usual care; remaining tests all generated more QALYs than usual care	Usual care dominant over Abbott Clearview Exact Strep A cassette or test strip ICERs for remaining tests suggest testing is more costly but more effective than usual care (primary and secondary care)	<i>Primary care</i> Results were similar to the base-case results, with ICERs indicating that usual care dominated two (the Abbott Clearview Strep A tests) of the 14 tests. The probability for testing to be cost-effective was zero at a cost-effectiveness threshold of £20,000 per QALY in all scenarios, regardless of the test used. The base-case ICERs are highly sensitive to model assumptions and inputs. <i>Secondary care</i> Results mirrored the primary care model.
Little (2014)	Partially applicable	Patients aged ≥3y; acute sore throat	Costs per patient:	QALYs per patient:	£74,286 (14 day) £24,528 (28 day)	At threshold of £30,000/QALY, the

	Intervention includes FeverPAIN which is not relevant to review inclusion criteria; includes children; results may still be useful given UK-based study and NHS perspective	Lancefield group A/C/G streptococci Clinical scoring algorithm (FeverPAIN) +RADT if score high on algorithm UK NHS perspective.	RADT £48.50 Clinical algorithm: £45.90 Control: £49.70	RADT 0.018 Clinical algorithm: 0.017 Control 0.017		probabilities of cost-effectiveness are 25%, 40% and 35%, for the delayed control, clinical algorithm and RADT groups, respectively (14-day results). For the 28-day QALY gain, the same values are 28%, 38% and 35%.
Other tests						
Michaelidis (2014)	Partially applicable US-based but took a healthcare system perspective; results may be relevant	Adults with ARTI symptoms POC procalcitonin-guided antibiotic therapy US healthcare system, outpatient clinic.	Costs per patient Patients judged to require antibiotics: Test \$51 No test \$29 Prior to any antibiotic decision: Test: \$49 No test \$15	QALYs per patient Patients judged to require antibiotics: Test: 0.00746 No test: 0.00765 Prior to any antibiotic decision: Test: 0.00743 No test: 0.00749	Patients judged to require antibiotics: \$118,828 Prior to any antibiotic decision: \$575,249	None conducted for cost-utility analyses.
Nicholson (2014)	Directly applicable	Patients aged >65y, or >18y with chronic heart or lung disease; acute exacerbation of chronic cardio-pulmonary illness or influenza-like illness of <7 days	Cost per patient: PCR: £1,978 Traditional: £2,327 POCT: £2,159	QALYs per patient PCR: 0.007779 Traditional: 0.007588 POCT: 0.008035	Traditional laboratory culture dominated. POCT compared to PCR: £734,717	Price reduction of the tests has a relatively small impact on results. Ranking of the strategies remains the same as the base case.

		<p>Influenza A and B, respiratory syncytial virus and pneumococcal infection</p> <p>Rapid near-patient diagnostic tests (Quidel for influenza, and BinaxNOW for the pneumococcal antigen)</p> <p>UK NHS perspective, hospital setting</p>				<p>Probabilities (of error) of being cost-effective at WTP thresholds of £20,000 and £30,000 respectively are 0.183 and 0.186 for the POCT; 0.783 and 0.781 for PCR and 0.034 and 0.033 for the traditional strategy.</p>
<p>Abbreviations: CI = confidence interval; DP = delayed antibiotic prescribing; ICER = incremental cost effectiveness ratio; QALY = quality adjusted life years; RADT = rapid antigen detection test; POCT = point of care test; PCR = polymerase chain reaction; WTP = willingness to pay; POC = point of care; ARTI = acute respiratory tract infection; LRTI = lower respiratory tract infection; ICER = incremental cost effectiveness ratio; NMB = net monetary benefit; CEAC = cost effectiveness acceptability curve</p>						

1

1 **1.1.9 Economic model**

2 Economic modelling was not undertaken for any of the review questions.

3 **1.1.10 Unit costs**

4 **Near patient rapid tests**

5 Unit costs of near-patient tests are presented in Table .

6 Unit costs for the different C-reactive protein tests are taken from publicly available sources.
7 These include the cost of the test cartridges and the cost of the analyser. For tests to detect
8 procalcitonin or strep A, unit costs were obtained from relevant NICE guidance. All costs are
9 exclusive of VAT.

10 Unit costs of tests for pneumococcal and influenza antigens could not be located in publicly
11 available sources, and therefore were taken from economic evaluations of these tests. The
12 costs in Table for these tests also include the staff time to perform the test together with the
13 cost of the equipment and materials.

14 **Table 21: Costs of rapid near-patient tests**

Test	Cost	Source
C-reactive protein tests		
QuikRead	£1,050 for the analyser £215 for 50 single use tests	NICE Medtech Innovation Briefing [MIB78] https://www.nice.org.uk/advice/mib78
COBAS Liat	£22,396.78 for the analyser	NHS Supply chain (accessed 25/07/23) https://my.supplychain.nhs.uk/catalogue/product/hhh3461
LumiraDX	£5,400 for the analyser £3.80 per test strip	NHS Supply chain https://my.supplychain.nhs.uk/catalogue/product/hhh3868 https://my.supplychain.nhs.uk/catalogue/product/hhh3873
Alere Afinion	£1,200 for the analyser £3.50 per test cartridge	NICE Medtech Innovation Briefing [MIB81] https://www.nice.org.uk/advice/mib81

FebriDx	£12.75 per test	NICE Medtech Innovation Briefing [MIB224] Test for CRP and myxovirus resistance protein A (MxA) https://www.nice.org.uk/advice/mib224
Strep A tests		
Clearview Exact Strep A cassette (Abbott)	£2.72	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
Clearview Exact Strep A dipstick (Abbott)	£1.92	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
Strep A rapid test cassette (Biopanda Reagents)	£0.82	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
Strep A rapid test dipstick (Biopanda Reagents)	£0.64	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
QuikRead Go Strep A test kit (Orion Diagnostica)	£4.34	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
Alere TestPack Plus Strep A cassette (Abbott)	£2.70	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
Alere i Strep A 2 (Abbott)	£22.94	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
Cobas Strep A assay on Liat system	£35	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]

(Roche Diagnostics)		
Xpert Xpress Strep A (Cepheid)	£4.25	NICE diagnostic guidance for rapid tests for group A streptococcal infections in people with a sore throat [DG38]
Other tests		
Pneumococcal antigen	£25.56 per test	Includes staffing and materials (BinaxNOW) <i>Source: Nicholson (2014)</i>
Influenza antigen	£15.83 per test	Includes staffing and materials (Quidel® QuickVue Influenza A + B) <i>Source: Nicholson (2014)</i>
Procalcitonin	£13.79 per test	From DG18 : procalcitonin testing for diagnosing and monitoring sepsis

1

2 Antibiotics

3 Unit cost of courses of antimicrobials for treating community-acquired pneumonia for adults
4 aged 18 and over, recommended in [NICE Guideline \[NG138\]](#), are provided in Table .

5 **Table 22: Unit costs of antibiotics for community-acquired pneumonia**

Severity of pneumonia	Treatment	Cost of treatment
Low severity	Amoxicillin (500mg 3 times a day for 5 days)	£1.77
Low severity (penicillin allergy)	Doxycycline (200 mg on first day, then 100 mg once a day for 4 days)	£1.10
	Clarithromycin (500 mg twice a day for 5 days)	£4.08
Medium severity	Amoxicillin (500mg 3 times a day for 5 days)	£5.85
	Clarithromycin (500 mg twice a day for 5 days)	

Medium severity (if penicillin allergy)	Doxycycline (200 mg on first day, then 100 mg once a day for 4 days)	£1.10
	Clarithromycin (500 mg twice a day for 5 days)	£4.08
High severity	Co -amoxiclav (125mg/500mg 3 times a day for 5 days)	£6.10
	Clarithromycin (500 mg twice a day for 5 days)	
High severity (if penicillin allergy)	Levofloxacin (500 mg twice a day for 5 days)	£18.90

1 *Source: NHS Electronic drug tariff (accessed 12/07/2023)*

2 **Locations of care**

3 The cost of hospital admission and ITU admission for people with pneumonia and lower
4 respiratory tract infection are represented in Table 23 below, to aid consideration of cost
5 effectiveness on the escalation of care for people judged to have severe illness.

1 **Table 23: Unit costs of hospital admission**

Parameter	Average unit cost
Cost of hospital admission for pneumonia	
Lobar, Atypical or Viral Pneumonia, with Multiple Interventions	£7,258
Lobar, Atypical or Viral Pneumonia, with Single Intervention	£4,534
Lobar, Atypical or Viral Pneumonia, without Interventions	£2,259
Cost of hospital admission for lower respiratory tract infection	
Unspecified Acute Lower Respiratory Infection with Interventions	£4,569
Unspecified Acute Lower Respiratory Infection without Interventions	£1,531
Cost of ITU	
Adult Critical Care, 6 or more Organs Supported	£2,985
Adult Critical Care, 5 Organs Supported	£2,892
Adult Critical Care, 4 Organs Supported	£2,861
Adult Critical Care, 3 Organs Supported	£2,587
Adult Critical Care, 2 Organs Supported	£2,278
Adult Critical Care, 1 Organ Supported	£1,587
Adult Critical Care, 0 Organs Supported	£1,640

2 *Source: NHS cost collection 2021/22*

3 **1.1.11 The committee's discussion and interpretation of the evidence**

4 The committee discussion below relates to all of the evidence analysed in reviews A, B and
5 C and summarised in this document.

1 **1.1.11.1. The outcomes that matter most**

2 None of the included studies provided evidence about virtual wards or ARI hubs. This meant
3 that the committee were unable to make recommendations about initial management of
4 people in terms of a care pathway that might include virtual wards or referral through acute
5 respiratory infection hubs. They noted that some of the severity scores might lend
6 themselves to this, but they tended to be scores that were not validated or tested in
7 undifferentiated populations in primary care.

8 The committee agreed that for review question 1 (see evidence review [A]) and review
9 question 2 (see evidence review [B]) the key outcomes related to severe illness so they were
10 most interested in whether signs symptoms and scores could predict mortality,
11 hospitalisation (including ICU) or other kinds of escalation of care. They were also interested
12 in quality-of-life outcomes, such as patient acceptability and preference. They agreed that
13 signs and symptoms, and physiological parameters including early warning scores (EWS)
14 that could accurately predict severe illness (for which hospitalisation or mortality may be
15 used as proxies) would be most useful to healthcare practitioners who were making an initial
16 assessment of people with suspected ARI because they would help them to decide which
17 care pathway best matched their level of risk of severe illness. The committee saw evidence
18 for outcomes of mortality and escalation of care, and also for antibiotic prescribing, however
19 for most point of care tests (POCT) there were only data for mortality. Only C-reactive protein
20 (CRP) had outcome data for hospital admissions.

21 For review question 3 (see evidence review [C]), the committee were interested in diagnostic
22 outcomes such as sensitivity, specificity and receiver-operator characteristic curves and area
23 under the curve calculations. The question related to the prescribing of antibiotics (both
24 antimicrobial and antiviral), so whilst acknowledging the importance of test sensitivity, in the
25 interests of good antimicrobial stewardship, the committee agreed that specificity was the
26 most important outcome since more specific tests would mean that the people who received
27 medication would be more likely to have an infection. They agreed that a specificity of 75%
28 was a reasonable value to use for this purpose.

29 **1.1.11.2 The quality of the evidence**

30 The committee considered the evidence for the usefulness of symptoms, signs and EWS for
31 predicting mortality and escalation of care (including hospital admission). This included
32 evidence for absence of cough, fever, anterior cervical adenopathy, tender anterior cervical
33 adenopathy and any exudates in people with suspected pharyngitis, and for the following
34 EWS in suspected ARI (including pneumonia):

35 Centor, CRB-65, CURB-65, PSI, CREWS, NEWS, SIRS, SEWS, S-NEWS, ATS 2001,
36 IDSA/ATS 2007, SCAP/CURXO-80, SMART-COP and REA-ICU.

37 Since the review was a tertiary review (a review of systematic reviews), the quality of the
38 included studies was assessed with the ROBIS tool. Using this tool, 5 included reviews were
39 at low risk of bias, 1 was at unclear risk of bias and 3 were at high risk of bias.

40 The review of POCT did not find any evidence for several of the tests that were outlined in
41 the review protocol:

- 42 • Rapid PCR tests

- 1 • Urinary antigen tests
- 2 • Serum sodium
- 3 • Urea nitrogen
- 4 • Partial pressure O²
- 5 • Blood gases
- 6 • Full blood count
- 7 • White blood cell count
- 8 • Myxovirus resistance protein A
- 9 • TNF-related apoptosis-induced ligand (TRAIL)

10 However, there was evidence for CRP and procalcitonin. There was also evidence on rapid
11 antigen tests for Group A Streptococcus and influenza. All of the outcomes reported by this
12 review were assessed using GRADE as being of very low confidence, which means that
13 further research is likely to change the estimated effectiveness of the tests. The main reason
14 for downgrading was for methodological limitations, with very serious methodological
15 concerns being noted for all of the included studies. This was mostly due to uncertainties
16 around selection bias and high risk of bias due to lack of blinding and incomplete outcome
17 data reporting.

18 For the diagnostic question about identifying bacterial or viral infection, the committee were
19 reassured that there was a range of evidence for symptoms and signs, CRP, procalcitonin
20 and white cell differential count. There was also evidence for viral tests for influenza and for
21 respiratory syncytial virus (RSV). The evidence showed that point of care microbiological
22 tests for people with suspected ARIs were not accurate enough to determine whether an
23 infection was bacterial or viral. The committee noted that the evidence showed that some
24 tests for influenza virus and respiratory syncytial virus (RSV) were quite accurate, especially
25 as rule in tests (i.e. they had high specificity), however the most accurate tests were ones
26 that would not normally be available outside of hospital settings. The committee also noted
27 that normally, decisions about prescribing for flu are made by the UKHSA and communicated
28 locally via communicable disease control units. Therefore, they did not recommend testing
29 for flu. The evidence for symptoms and signs was of very low to moderate quality assessed
30 using GRADE. The main reasons for downgrading were risk of bias/methodological
31 limitations and imprecision. The evidence for biomarker tests and for flu/RSV tests was also
32 assessed using GRADE as ranging from very low to moderate due to methodological
33 limitations, imprecision and indirectness.

34 The authors also note that for some outcomes it was not possible to assess imprecision or
35 inconsistency, so the committee noted that some of the GRADE assessments may be
36 spuriously high.

37 Overall, the quality of the evidence was poor, with the majority of the evidence being
38 assessed as low or very low confidence. This meant that the committee had to defer to
39 clinical judgment in many recommendations, and to make a lower strength recommendation
40 than they would have been able to make if the evidence had been more robust. None of the
41 evidence came from studies that included remote consultations and therefore the committee

1 had to use their expertise and experience to extrapolate from the evidence about face-to-
2 face consultations to remote consultations.

3 **1.1.11.3 Benefits and harms**

4 The committee noted that there are NICE guidelines that have some overlap with the acute
5 respiratory infection guideline, for example [NICE's guidelines on antimicrobial prescribing for](#)
6 [acute sore throat](#) and [acute cough](#). This is partly because they deal with symptoms rather
7 than illnesses. The committee noted especially that the cough and sore throat management
8 guidelines were useful for people who presented with those symptoms but might not have an
9 acute lower respiratory infection, therefore they added links to these guidelines.

10 **Remote consultations**

11 The committee discussed the evidence from the review about the usefulness of signs
12 symptoms and early warning scores. They noted that although the evidence came from a
13 range of settings, including primary care, emergency departments and outpatients, and in
14 one case nursing homes, none of the systematic reviews included in the evidence has
15 assessed any of the tools in remote consultations.

16 The committee discussed remote consultations. They noted that a remote consultation can
17 vary from a text message or an email to a video-based call (such as Zoom or Skype). They
18 noted that the nature of the assessment that could be undertaken would depend on the
19 medium of the consultation. For example, a video call might be adequate for a healthcare
20 practitioner to notice pallor or sweating or laboured breathing, whereas a telephone
21 conversation would likely not allow this. They also agreed that not all people were conversant
22 with using all of the different forms of communication, and that for some people a video
23 consultation (for example) might prove anxiety provoking, or a person might lack the
24 necessary equipment and skills to participate in the consultation at all. They discussed the
25 equipment that might be needed to assess some symptoms. They agreed that some people
26 have a pulse-oximeter at home since the COVID-19 pandemic, and that some people have
27 blood pressure machines and thermometers at home. They pointed out that while many of
28 these machines are reliable, there were others, for example smart watches, where readings
29 might be less accurate. They also require proper use, which the healthcare practitioner might
30 not be sure of if the consultation does not have a video component, especially if the person
31 was confused or not comfortable using technology.

32 Based their discussions, the committee agreed that the most important thing at the beginning
33 of a remote consultation was to establish whether the person was competent to use the
34 method of consultation, or whether another method or face-to-face appointment might be
35 more appropriate.

36 The committee agreed it was also important to rule out red flags early in the consultation and
37 to assess people for possible sepsis and for pneumonia. The committee included a
38 recommendation about this and linked to NICE's [sepsis: recognition, diagnosis and early](#)
39 [management](#) guideline. Remote consultations are provided by a range of healthcare
40 practitioners with different levels of clinical acumen and judgment. To support practitioners in
41 deciding whether a person might have pneumonia, the committee included a list of
42 symptoms that were found to have a specificity of more than 75% for bacterial pneumonia
43 following the evidence in review [C] (tachypnoea, wheezing, low oxygen saturations, fever,
44 low systolic BP, tachycardia, diarrhoea, impaired consciousness). They referenced the same

1 list in the recommendations for face-to-face assessment but added assessment of crackles
2 and reduced breath sounds to the in-person recommendation on the basis that it would never
3 be possible to assess this remotely. The committee acknowledged that pneumonia can be
4 caused by a viral infection, and it is difficult to distinguish it from a bacterial infection.
5 Therefore, they agreed that the symptoms and signs I could be used to make a clinical
6 diagnosis of viral pneumonia too. The confidence in this evidence ranged from very low to
7 moderate, with most of the symptoms rating very low in GRADE (5 out of 9 symptoms), so
8 the committee offered it as a guide to symptoms that might be useful in making a clinical
9 diagnosis of pneumonia rather than as a definitive list. The committee were interested in the
10 potential for EWS to be used in remote consultations (if the right equipment were available)
11 and made a research recommendation to explore this (see [appendix K](#)).

12 The committee agreed that if the healthcare practitioner doing the assessment thought that
13 the person might have pneumonia, or if they thought the person had a respiratory infection
14 that was exacerbating a co-existing condition (such as COPD) that they should be seen for a
15 face-to face appointment for a more complete assessment and prescription of an antibiotic if
16 necessary.

17 The committee discussed where the face-to-face appointment should take place and agreed
18 that it would depend on the level of concern for the person, based on their symptoms and co-
19 morbidities. They agreed that in many cases, if a person needed a face-to-face appointment,
20 this could be at a GP surgery, or a referral to an acute respiratory infection hub if one was
21 operating in the area. However, if a person was severely ill or was deteriorating quickly then
22 an emergency department, or sometimes an emergency ambulance might be the
23 proportionate response.

24 The committee agreed that antibiotics should not be prescribed for respiratory infections on
25 the basis of a remote consultation alone, and that this represented poor antimicrobial
26 stewardship. If a person had suspected pneumonia, or a respiratory infection that might
27 require antibiotic treatment they should be seen in person. This position was supported by
28 the lack of evidence for the usefulness of symptoms and signs to distinguish between
29 bacterial and viral infections in evidence review [C].

30 **In-person consultations**

31 In addition to their discussions about symptoms and signs, the committee also considered
32 the evidence for rapid point of care tests that could be used in face-to-face appointments
33 (evidence review [B]). They noted that all of the evidence was of very low quality and that
34 they could not have much confidence in the effect estimates. They were also aware that the
35 NICE pneumonia guideline made recommendations about assessing lower respiratory tract
36 infections and suspected pneumonia in primary care settings, and they were reassured that
37 there was consistency with NICE's guideline on [pneumonia in adults: diagnosis and
38 management](#).


39 The committee discussed the evidence for microbiological and influenza tests for determining
40 whether to prescribe antibiotics to people with a suspected ARI. They noted a range of point
41 of care tests were available, but that in general they either required expensive equipment or
42 required a lot of time to give a result, and none of them provided a clear advantage in terms
43 of improving outcomes or cost saving over clinical judgement. The committee agreed that in
44 general the use of antivirals for suspected flu is directed by the UKHSA when influenza
45 season is officially announced and that this should drive antiviral prescribing in those

1 circumstances. Based on those considerations, the committee agreed to align with the
2 pneumonia guideline and recommended that clinicians do not use microbiological tests to
3 help them decide whether or not to prescribe antibiotics. The evidence for POCT
4 microbiological tests was of poor quality and there was low certainty in the evidence
5 Therefore, the committee agreed that some of them may perform better in more robust trials,
6 so they made a research recommendation to support this (see [appendix K](#)).

7 The committee discussed the use of biomarkers, particularly C-reactive protein (CRP) as an
8 aid to making a decision to prescribe antibiotics in ARI. Very low to moderate quality
9 evidence assessed the sensitivity and specificity of CRP for detecting viral or bacterial ARI.
10 They were interested that the evidence shows that CRP tests reduce the numbers of
11 antibiotics prescribed both at index consultation and within 28 days of that consultation by a
12 (statistically) significant amount, although the evidence was very uncertain. There was also
13 some evidence (also very uncertain) that CRP testing might increase the likelihood of a
14 further consultation within 28 days. They discussed the limitations of CRP testing because of
15 the time lag for onset of symptoms with infections (which corresponds to presence of CRPs),
16 so a sample taken early in the course of infection could be falsely reassuring.

17 The committee noted that for CRP tests, the trend was as expected, with lower values having
18 a high sensitivity and low specificity, and high values having a lower sensitivity and a higher
19 specificity (see figure 1). The committee discussed antimicrobial stewardship alongside the
20 risks to people of not prescribing antibiotics when they did have an ARI. On the balance of all
21 the factors, and acknowledging the importance of test sensitivity, the committee agreed that
22 specificity was the most important measure, mainly for good antimicrobial stewardship. A
23 person should almost certainly have an ARI before antibiotics are considered. They noted
24 that the evidence showed that at a CRP of >100 mg/l a person is more than 90% likely to
25 have a bacterial infection, and antibiotics should be prescribed. At values lower than 100mg/l
26 the specificity fell and the sensitivity rose, meaning that the lower the CRP value, the more
27 likely a false positive result. At a threshold of 20mg/l the specificity had fallen to just over
28 50% meaning that almost half of the people who test positive will not have an infection.
29 Therefore, the committee agreed that antibiotics should not normally be prescribed below
30 this level. In between 20 and 100 mg/l they agreed that it was clinical judgment that should
31 determine the strategy, but suggested, based on their experience that delayed prescriptions
32 might be a good option. The committee agreed, taking into account the low certainty in the
33 evidence and based on their clinical experience, CRP was a tool that could assist with
34 making a decision about antibiotics, but that it should only be used when clinical assessment
35 has not provided an adequate diagnosis and the clinician remains unsure about whether or
36 not to prescribe antibiotics.

1 **Figure 1**



2
3
4

*Based on data from evidence review [C]

5 The committee discussed early warning scores. They were surprised that there were so few
6 studies researching the most commonly used scores, and that almost all of this evidence
7 was in acute settings. They noted there were small amounts of evidence for a range of
8 scores that are not in common use.

9 Evidence for EWS scores showed that patients in low-risk PSI and CRB-65 classes were
10 found to be at low risk of death when managed as outpatients, but that they might over
11 predict in primary care settings.

12 They noted that some of the EWS had requirements that meant they would not be useful in
13 most primary care encounters, for example the Pneumonia Severity Index (PSI) for
14 assessing people with suspected pneumonia included a range of measures that are usually
15 only available as an inpatient in hospital (for example arterial pH, haematocrit). Similarly,
16 CURB-65 requires a measurement of blood urea nitrogen so is not suitable for primary care
17 settings.

18 They agreed that tools such as the NEWS2 and its associated tools (for example MEWS)
19 were promising and generally had favourable results, especially for prediction of mortality in
20 people with respiratory distress and prediction of ICU admission. However, all of the
21 evaluations of NEWS2 were in emergency department or admissions unit populations, and it
22 is unclear whether these can be extrapolated to the general population or to primary care.
23 The committee were aware of the [reservations about NEWS2 expressed by the Royal](#)
24 [College of General Practitioners](#) because they have often not been validated in primary care,
25 and agreed their reservations were sensible. The committee were keen for research to be
26 conducted about the effectiveness of NEWS2 for predicting severe illness in pneumonia in
27 primary care and other non-hospital settings, and for all EWS in ARI hubs and made
28 recommendations to research this (see [appendix K](#)).

1 Overall, the committee agreed that currently the most useful early warning score to use in
2 people with a clinical diagnosis of pneumonia, in primary care and non-hospital settings was
3 CRB-65. This is because the test does not require extensive testing or access to tests that
4 are not likely to be available in non-hospital settings, and because people in low CRB-65
5 categories were shown in the evidence to be at low risk of mortality. The CRB-65 test
6 assesses 4 attributes and assigns a score of 0 or 1 to each attribute to generate a score of 0
7 – 4 for the risk of the pneumonia leading to all-cause death at 30 days. Mortality is very low
8 in people with a score of 0 (<1%), with a score of 1 or 2 it is 1-10%, and mortality rises to
9 over 10% with a score of 3 or 4^a. The committee agreed that this was a useful supplement to
10 clinical judgment, but that decisions about a person’s care should not be based on the CRB-
11 65 alone. They noted that this was consistent with recommendations in the NICE pneumonia
12 guideline.

13 The committee agreed that people with a CRB-65 score of 0 could be managed in an
14 outpatient setting, unless there were specific concerns about them. They made a consensus
15 recommendation that, for people who scored 1 or 2 on CRB-65, a shared decision should be
16 made with the person about whether they could be adequately cared for at home, or whether
17 they should be referred to a virtual ward or some other form of intermediate care. This
18 decision would need to consider the person’s frailty and any co-morbidities alongside their
19 social circumstances and their preferences. For people with a score of 3 or 4 the committee
20 agreed that clinicians would want to consider a hospital assessment since risk of mortality in
21 those people was over 10%.

22 The committee also agreed that for people with ARIs that are not pneumonia, frailty and co-
23 morbidities should be take into account when deciding on their treatment. ARIs can cause
24 exacerbations of underlying conditions and may make people more vulnerable to severe
25 outcomes. The committee agreed that for these people diagnostic thresholds and therefore
26 likelihood of antibiotic prescription would be lower than for the general population in terms of
27 providing antimicrobials or escalating care, for example to a virtual ward.

28 The committee discussed the general epidemiology of ARIs, pointing out that they were
29 transmissible diseases that usually followed a seasonal pattern. As a result of this cyclical
30 pattern, the prevalence of ARIs varies throughout the year, normally peaking in winter.
31 Information from UKHSA about the national pattern of these diseases is important in deciding
32 on diagnosis and treatment and clinicians should follow updates from UKHSA and advice
33 from them about diagnosis and prescribing during seasons of high ARI prevalence.
34

35 **1.1.11.4 Cost effectiveness and resource use**

36 The committee reviewed economic evidence from the existing literature on the cost
37 effectiveness of strategies on the initial assessment and management of suspected ARIs.

38 **Using symptoms, signs and early warning scores to assess and manage people with** 39 **suspected ARI**

40 The evidence from the literature on the cost effectiveness of the use of different symptoms,
41 signs and early warning scores came from one cost-effectiveness analysis (Little et al. 2014),

^a Lim WS, van der Eerden MM, Laing R, et al. (2003) Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 58: 377–82

1 which evaluated the assessment and management of people in primary care with acute sore
2 throat symptoms. The analysis found that the use of a clinical symptom score (FeverPAIN) to
3 guide antibiotic prescribing is a cost-effective approach compared with a delayed antibiotic
4 prescribing strategy (standard care): although they result in similar numbers of QALYs, the
5 use of a clinical symptom score provides lower costs over a 28-day period.

6 The committee noted that the sole economic evidence in this area was for a short-term upper
7 respiratory tract infection. They considered that this evidence was consistent with that used
8 to support the sore throat guideline and decided to cross refer to that guideline, along with
9 guidelines on management on other ARI symptoms. The main focus of this guideline was
10 decided to be on the management of lower respiratory tract infections and pneumonia, which
11 have greater consequences to the patient and to the healthcare system if not managed
12 appropriately.

13 There were no studies that evaluated the cost effectiveness of initial assessment or triaging
14 strategies in people with ARIs that are more likely to require intensive care, such as
15 pneumonia. Identifying the symptoms associated with pneumonia that could be assessed
16 remotely and recommending that people presenting with these should receive a face-to-face
17 assessment in order to receive a more thorough assessment will help the healthcare
18 practitioner assess possible red flags that may require urgent action. By recommending that
19 these people receive further care means that healthcare resources such as GP visits and ED
20 assessment are used by those who need it most, and will support a more efficient healthcare
21 system at times of pressure.

22 The committee agreed that antibiotics should not be prescribed based on a remote
23 assessment alone. Recommending a face-to-face assessment for these people will save
24 costs by reducing unnecessary prescriptions by not giving them to those unlikely to benefit
25 from them, and improves antimicrobial stewardship, which has long-term patient and
26 economic benefits.

27 **Rapid tests to inform triage and antibiotic prescribing decisions**

28 Results from four cost-effectiveness studies suggest that rapid tests for C-reactive protein
29 (CRP) given in primary care to people with symptoms of an ARI or a COPD exacerbation
30 may be cost-effective when identifying whether their symptoms are due to a bacterial or viral
31 infection and in guiding use of antibiotics.

32 In all cost effectiveness studies, people experienced a higher number of mean QALYs with
33 the usage of CRP point of care tests (POCTs). The committee questioned the validity of this
34 finding, and discussed whether avoiding unnecessary antibiotics would have an impact on
35 those who do not need them. Some studies indicated that the favourable outcomes were due
36 to a reduction in the duration of ARIs (although the studies and the committee were unclear
37 on the reason for this) and the avoidance of antibiotic-related adverse events in a small
38 proportion of people. They concluded that the QALY gains were very small in reality and may
39 not be clinically significant, but that using CRP POCT to inform an antibiotic reduction
40 strategy was not detrimental to patient outcomes.

41 The committee then questioned whether the use of CRP POCTs can be considered cost
42 neutral or cost saving. The committee were also presented with a range of unit costs for
43 different POCTs and courses of antibiotics (see Table and Table) and noted the relatively
44 small cost of antibiotics (ranging from approximately £1 to £6), depending on severity of
45 pneumonia) compared to the cost of CRP testing. The cost of CRP testing is variable

1 depending on the system that is used, but an economic evaluation in the review estimated
2 that the total cost of a CRP test in primary care was £9.58 (2016/17 cost), once all relevant
3 costs including staff costs, all consumables and materials, quality control and the need to re-
4 test a proportion of people were taken into account. These cost findings are generally
5 supported by the economic evaluations in the review, which found testing to be more
6 expensive. However, while most studies only considered costs and outcomes in the short-
7 term, there was one economic evaluation that modelled outcomes over a much longer time
8 horizon and found that CRP POCTs provided cost savings overall due to favourable re-
9 consultation and reinfection rates.

10 The committee also discussed the resource implications of providing CRP tests to people
11 who present with ARI symptoms, and noted that there would be challenges in managing
12 tests throughput in a primary care setting. One study (Holmes, 2018) demonstrated that CRP
13 POCT is more likely to be cost effective if it was used strategically, and conducted a scenario
14 in line with the recommendations in the current NICE pneumonia guideline (CG191). In this
15 scenario, CRP tests are provided only when clinical assessment is not conclusive, and
16 antibiotics are not routinely offered if CRP is <20mg/L or a delayed prescription is given if
17 CRP is between 20-100mg/L. Considering both the higher likelihood of being cost effective
18 and the mitigation of the resource impact, the committee made recommendations in line with
19 this scenario for the use of CRP POCT.

20 Other economic evaluations considered by the committee evaluated rapid tests for
21 procalcitonin, streptococci, influenza and the pneumococcal antigen. They found that the
22 evidence is too limited to draw conclusions or did not indicate good value for money for other
23 rapid tests that were evaluated. Therefore, the committee recommended that these should
24 not be used to assess patients in primary care.

25 **Antimicrobial resistance**

26 The committee agreed that a key motivation for optimising the use of antibiotics in ARIs is to
27 reduce future antimicrobial resistance associated with unnecessary antibiotic prescribing.
28 Strategies to minimise AMR can reduce long-term costs, and improve patient outcomes or
29 avoid patient harm. However, there is no standardised methodology for estimating the costs
30 and consequences associated with AMR in an economic evaluation. Two studies did make
31 some attempt to incorporate an estimated cost associated with AMR into their sensitivity
32 analyses, but the validity of their calculations was unclear. Therefore, the committee made a
33 research recommendation on the best methods to incorporate this into economic evaluations
34 (see Appendix K– Research recommendations – full details).

35 **Location of care**

36 Severity assessment tools may be used by clinicians to guide hospital admission or ITU
37 assessment according to the severity of illness. As there were no economic evaluations on
38 the use of CRB-65 scores in primary care to assess and manage people with pneumonia, the
39 committee were provided with the cost of hospital admission and ITU admission are
40 represented in Table 23 to aid consideration of cost effectiveness. The committee considered
41 that CRB-65 is an accurate measure for assessing the risk of pneumonia patients, and
42 therefore it will also be cost effective to use it to inform their management, as they will ensure
43 the most appropriate care is provided to patients and the resources are therefore used
44 appropriately.

1 The committee agreed that people with a CRB-65 score of zero can be safely managed at
2 home, and that people with a CRB-65 score of three should be managed more closely in
3 hospital, due to the higher mortality risk in this group. Supported home-based care such as
4 virtual wards were discussed as appropriate locations of care for people with CRB-65 score
5 of 1 or 2, when used alongside clinical judgement following a face-to-face assessment. At the
6 time of this guideline, NHS England has started to roll out more virtual wards for two
7 pathways, including ARI, with a target to provide above 10,000 beds by the next influenza
8 season. As an alternative solution to inpatient hospital care, admission to virtual wards can
9 help reduce pressure on the healthcare system, particularly at times when the demand for
10 urgent and emergency care is increased. The economic benefits of virtual wards in people
11 with ARI and other conditions are being evaluated in other ongoing workstreams at NICE.
12 The [technologies that support virtual wards](#) are also currently being evaluated, and NICE is
13 accessing and reviewing real-world economic data from NHS sites that have implemented
14 virtual wards to provide general advice to support economic business case development. As
15 part of the development of this guideline a [review of the existing economic literature](#) found
16 that they are usually reported as cost saving, but uncertainties remain in this evidence.

17 **1.1.12 Recommendations supported by this evidence review**

18 This evidence summary and the three [evidence reviews](#) support the recommendations and
19 the research recommendation on acute respiratory infection.

20 **1.1.13 References – included studies**

21 **1.1.13.1 Effectiveness and diagnostic**

22 See [individual reviews](#) for full references of included studies.

23 **1.1.13.2 Economic**

24 **RQ1: Signs and symptoms**

25 Little P, Hobbs FD, Moore M, Mant D, Williamson I, McNulty C, et al. PRImary care
26 Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic
27 adaptive randomised controlled trial with nested qualitative study and cost-effectiveness
28 study. *Health Technol Assess*. 2014;18(6): 1-101. <http://dx.doi.org/10.3310/hta18060>

29 **RQ2: rapid, near-patient tests**

30 Francis NA, Gillespie D, White P, Bates J, Lowe R, Sewell B, et al. C-reactive protein point-
31 of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive
32 pulmonary disease: the PACE RCT. *Health Technol Assess* 2020;24(15):1-108.
33 <http://dx.doi.org/10.3310/hta24150>

34 Fraser H, Gallacher D, Achana F, Court R, Taylor-Phillips S, Nduka C, et al. Rapid antigen
35 detection and molecular tests for group A streptococcal infections for acute sore throat:
36 systematic reviews and economic evaluation. *Health Technol Assess* 2020;24(31):1-232.

- 1 Holmes EAF, Harris SD, Hughes A, Craine N, Hughes DA. Cost-Effectiveness Analysis of
2 the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in
3 Primary Care. *Antibiotics* 2018;**7**(4):07. <http://dx.doi.org/10.3390/antibiotics7040106>
- 4 Hunter R. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract
5 infection in primary care in England. *Adv Ther* 2015;**32**(1):69-85.
6 <http://dx.doi.org/10.1007/s12325-015-0180-x>
- 7 Little P, Hobbs FD, Moore M, Mant D, Williamson I, McNulty C, et al. PRImary care
8 Streptococcal Management (PRISM) study: in vitro study, diagnostic cohorts and a pragmatic
9 adaptive randomised controlled trial with nested qualitative study and cost-effectiveness
10 study. *Health Technol Assess*. 2014;**18**(6): 1-101. <http://dx.doi.org/10.3310/hta18060>
- 11 Michaelidis CI, Zimmerman RK, Nowalk MP, Fine MJ, Smith KJ. Cost-effectiveness of
12 procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract
13 infections in adults. *J Gen Intern Med* 2014;**29**(4):579-86. [http://dx.doi.org/10.1007/s11606-](http://dx.doi.org/10.1007/s11606-013-2679-7)
14 [013-2679-7](http://dx.doi.org/10.1007/s11606-013-2679-7)
- 15 Nicholson KG, Abrams KR, Batham S, Medina MJ, Warren FC, Barer M, et al. Randomised
16 controlled trial and health economic evaluation of the impact of diagnostic testing for
17 influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the
18 management of acute admissions in the elderly and high-risk 18- to 64-year-olds. *Health*
19 *Technol Assess* 2014;**18**(36):1-274, vii-viii. <http://dx.doi.org/10.3310/hta18360>
- 20 Oppong R, Jit M, Smith RD, Butler CC, Melbye H, Molstad S, et al. Cost-effectiveness of
21 point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. *Br J Gen*
22 *Pract* 2013;**63**(612):e465-71. <http://dx.doi.org/10.3399/bjgp13X669185>

Appendices

Appendix A – Review protocols

See [individual reviews](#) for details of review protocols.

Appendix B – Literature search strategies

See [individual reviews](#) for details of searches undertaken and search strategies.

Appendix C – Effectiveness and diagnostic evidence study selection

See [individual reviews](#) for study selection details and PRISMA flow diagrams.

Appendix D – Effectiveness and diagnostic evidence

See [individual reviews](#) for evidence tables.

Appendix E – Forest plots

See [individual reviews](#) for forest plots.

Appendix F – GRADE tables

See [individual reviews](#) for GRADE tables.

Appendix G – Economic evidence study selection

See [individual reviews](#) for study selection details and PRISMA flow diagrams.

Appendix H – Economic evidence tables

See [individual reviews](#) for evidence tables.

Appendix I – Health economic model

No health economic modelling was undertaken for this guideline.

Appendix J – Excluded studies

See [individual reviews](#) for details of studies considered at full text and then excluded.

Appendix K– Research recommendations – full details

K1.1 Research recommendation

How accurate are early warning scores such as [NEWS2](#) and CRB-65, when applied in face-to-face and remote consultations in:

- primary care and other non-hospital, low-prevalence settings?
- ARI hubs?

And how can the scores/thresholds inform clinical decisions about care pathways, for example, sending people home, to virtual ARI wards, or to same day emergency care

K1.1.1 Why this is important

Early warning scores are widely used in secondary care and have been shown to be very effective in those settings for predicting mortality or severe illness. Although the tools are being used outside of secondary care, they have not been validated for this use and therefore the guideline committee could not recommend them as confidently as they would have liked. It is also unclear how the different scores on these tools can inform clinical decisions about the best care pathway and what levels of risk are appropriate markers for virtual ARI ward admission, or hospital admission.

K1.1.2 Rationale for research recommendation

Importance to 'patients' or the population	EWS may be useful tools to predict risk of severe illness or death in people with severe respiratory infections. Identifying this risk early means that people can be directed to the right services for their level of risk and avoid serious outcomes developing. For example to a respiratory virtual ward or to hospital.
Relevance to NICE guidance	EWS were considered as part of this update, but most of the data came from emergency departments and medical admissions. It may enable future recommendations to be made on this in any future updates of the NICE guidance
Relevance to the NHS	An accurate EWS will mean that people are cared for in the best place based on their risk of severe illness and death and will reduce the burden on secondary care of inappropriate referrals. There is also a potential cost saving element by reducing potential downstream cost through improved initial assessments and subsequent management of ARI.
National priorities	High. The role of virtual wards in managing acute respiratory infection is a priority.

Current evidence base	Reasonable data, but from different settings.
Equality considerations	EWS may need to have their thresholds modified to assess people with co-morbidities and frailty.

K1.1.3 Modified PICO table

Population	People aged over 16 with symptoms of an acute respiratory infection who are assessed by: <ul style="list-style-type: none"> • remote services (e.g. NHS 111) • primary care and other non-hospital, low-prevalence settings • ARI hubs
Prognostic tool	Early warning scores for predicting mortality or severe illness in people with acute respiratory infection (including pneumonia) used to determine care pathway
Outcome	<ul style="list-style-type: none"> • Severe illness (for example requiring unplanned hospital admission) • Mortality • Escalation of care • Antibiotic/antiviral use • Time to clinical cure/resolution of symptoms
Study design	Cohort study
Timeframe	Long term
Additional information	None

K2.1 Research recommendation

What is the role of point of care microbiological testing for guiding management of people with signs and symptoms of an acute respiratory tract infection, taking into account good antimicrobial stewardship, cost and cost-effectiveness of the tests, and time taken to do the test and get a result?

K2.1.1 Why this is important

Currently the evidence does not support rapid, near patient microbiological testing to determine the initial management of acute respiratory infections, for example to guide antimicrobial prescribing. However, faster and better tests are becoming available and these need to be assessed for their usefulness in non-hospital settings, paying

due regard to their cost, how long they take and how much expertise is required to do the test as well as their diagnostic accuracy.

K2.1.2 Rationale for research recommendation

Importance to 'patients' or the population	Swift and accurate diagnosis of the cause of a respiratory infection means that people can be given the best treatment for their condition.
Relevance to NICE guidance	The uncertainties about the value of microbiological testing outside of hospital, especially given the time taken to undertake tests and get results has an impact on their usefulness to guide initial management and means that currently people are managed on the basis of a clinical diagnosis.
Relevance to the NHS	Accurate identification of pathogens would lead to better prescribing of antimicrobials, improved antimicrobial stewardship, less resource waste through unnecessary antimicrobial prescription and less inappropriate referral to secondary care.
National priorities	Medium.
Current evidence base	Some data, see evidence reviews [B] and [C] and the committee discussion in this document.
Equality considerations	None known

K2.1.3 Modified PICO table

Population	People aged over 16 with symptoms of an acute respiratory infection who are assessed by: <ul style="list-style-type: none"> • primary care and other non-hospital, low-prevalence settings • ARI hubs
Intervention	Multiplex or single near patient, rapid tests (turnaround time \leq 45mins, also known as point of care tests) which are currently licensed and available for use in the UK to identify specific respiratory viral and bacterial infections, including influenza (A and B) and respiratory syncytial virus (RSV).
Comparator	Usual care
Outcome	<ul style="list-style-type: none"> • Cost-utility • HRQoL

	<ul style="list-style-type: none"> • Severe illness (for example requiring unplanned hospital admission) • Mortality • Escalation of care • Antibiotic/antiviral use • Time to clinical cure/resolution of symptoms
Study design	RCT with economic analysis
Timeframe	Short term
Additional information	None

K3.1 Research recommendation

How can we quantify the impact on antimicrobial resistance of interventions that safely reduce antibiotic prescribing, in terms of future healthcare costs and health-related quality of life?

K3.1.1 Why this is important

A key motivation for rapid testing is to optimise or prioritise antibiotic prescribing and subsequently reduce future antimicrobial resistance associated with unnecessary antibiotic prescribing. Frequently, areas across the country with high prescribing of antimicrobials also have high resistance to these treatments. Antimicrobial resistance means that standard treatments no longer work, infections are harder to control, the risk of the spread of infection to the rest of the population is increased, illness and hospital stays are prolonged, and the risk of death is greater.

However, there is no standardised, recommended methodology for estimating the costs and consequences associated with AMR in an economic evaluation. This is a key potential benefit of interventions which safely reduce antimicrobial prescribing, both in terms of reducing long-term costs and improving patient outcomes (or avoiding patient harm).

Incorporating the future costs and health consequences associated with AMR into economic evaluations of interventions that safely reduce antibiotic prescribing is likely to increase the likelihood of the intervention being cost-effective. In some instances, where the cost effectiveness of a strategy is borderline, factoring in the impact of AMR can change the outcome of an economic analysis.

K3.1.2 Rationale for research recommendation

Importance to 'patients' or the population	People with infections caused by resistant bacteria experience worse outcomes than those who can be managed with antimicrobials. Being able to capture the impact of antimicrobial
--	--

	resistance will allow the more effective management strategies to be identified for these people. Treating individuals appropriately will also have consequences for the population health, with reduced risk of the spread of the infection.
Relevance to NICE guidance	Adequate methods of assessing the impact of improving antimicrobial resistance will allow us to fully capture the impact of interventions that improve this outcome, and allow us to recommend the most appropriate means of managing people with ARI.
Relevance to the NHS	Being able to quantify the impact of antimicrobial resistance to inform decisions about care means that infections will be easier to control if better management strategies are implemented. Capacity in hospitals will be reduced as inpatient stays will be longer in those who are resistant to antimicrobials.
National priorities	Medium
Current evidence base	Some methods exist to quantify the cost of antimicrobial resistance, but these have not been standardised or validated
Equality considerations	None known

K3.1.3 Modified PICO table

Population	People aged over 16 with symptoms of an acute respiratory infection
Intervention	Reduced or targeted or optimised antibiotics prescribing for acute respiratory infection
Comparator	Standard antibiotic prescribing
Outcome	<ul style="list-style-type: none"> • Cost-utility • HRQoL • Healthcare costs • Severe illness (for example requiring unplanned hospital admission) • Mortality • Escalation of care • Time to clinical cure/resolution of symptoms
Study design	Analysis of (longitudinal) observational data with economic analysis
Timeframe	Long term
Additional information	None

Appendix L – Methods

See descriptions of methods in the [individual reviews](#).